CA1210395A - N-aryl-piperazinealkanamides - Google Patents

N-aryl-piperazinealkanamides

Info

Publication number
CA1210395A
CA1210395A CA000403950A CA403950A CA1210395A CA 1210395 A CA1210395 A CA 1210395A CA 000403950 A CA000403950 A CA 000403950A CA 403950 A CA403950 A CA 403950A CA 1210395 A CA1210395 A CA 1210395A
Authority
CA
Canada
Prior art keywords
formula
radical
aminocarbonyl
group
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000403950A
Other languages
French (fr)
Inventor
Georges Van Daele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of CA1210395A publication Critical patent/CA1210395A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40Halogenated unsaturated alcohols
    • C07C33/46Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/34Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/16Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Abstract

ABSTRACT
NOVEL N-ARYL-PIPERAZINEALKANAMIDES.

Novel N-aryl-piperazinealkanamides, having particular substituents attached to one of the carbon atoms of the piperazine ring, which compounds are useful to protect hearts from myocardial injury caused by ischaemia, anoxia or hypoxia.

Description

121V 3~35 JAB -3 71 NOVEL N-ARYL- PIP:ER_AZ~JEALKANAMIDE5 .

~L ~
Piperazine deriva'd~res, bearing on one of the carbon atoms a lower alkyloxycarbonyl radical or a hydroxymethyl radical, are de~r~ribed ~ Helv. Chim. Acta, 45, 23~3 2402 (1962). These piperazine derivati~re~ are taught to be useful a~ anthelmi~tic, antihistami~c~ and a~ psychotropic drugs.
- 10 N-aryl-4-(4,4-diarylbutyl)-1-piperazineahkanamide~, which ~re optio~ally sub~tituted o~ one o tl~e piperazane carbon atoms with a me~;hyl radical, are describe~ in U.S. Pat. NoO 3,267,104.
Said piperazinealkanamides are t;aught to be useful as coronary ~rasodilator, a~ local anaes~chetics, as central nervou system stim1?lat:ing agents and a3 an~dcarragee~i~ age~ts.
N-aryl-piperazineacetamides which are optionally subs~hlted in the piperazine part with a methyl or a phenyl radical, are de~c:ribed ~ C.A. 90, 168, 547 a~ useful intennediates irL the prepara~on of a~alge~ic~.
The compounds of the pre3ent in~ention differ fro~n the aforementioned prior art compou:nds by ~e na~ure of the substituents on the piperazine ~noiety ant by their pharmacological properties.
~\7 39~i The present invention is concerned with novel pipera7.i~e derivati~es, which may be repre ented by ~he formula R N~_~N Cm 2m 1$~ ( )' the ~tereochemically isomeric forms and ~e pharmaceutically 5 acceptable acid additior~ ~alt~ thereof, wherein R is a member selected from the group consisd~g of hydro-g~n and lower alkyl;

X is a member selected from the group c:orL~isting of hydroxy-lower alkyl, lower alkyloxylower alkyl, ami~ocarbonyl, mono- and 10 di(lower alkyl)aminocarbonyl, carboxyl~ lower alkyloxycarbonyl, (a~inocarbonyl)lower alkyl, Lmono- and di(lower alkyl)aminocarbonyl7-lower alkyl, carboxylower alkyl, (lower alk~loxycarbonyl)lower alkyl a~d (hydroxylower alkyl)am~ocarbonyl;

m is the i~teger 1 or 2;

R is a member selected from ~e g-oup con~isting of hydrogen and lower alkyl;

R3, R4 and R5 are each indepe~d~ntly selected frorn the group con~ Lg of hydrogen, hydroxy, lower alkyl, lower alkyloxy, halo, trifluoromethyl, lower alkylcarbonyl, aminocarbonyl, lower 20 alkyloxycarbonyl, cyano, amino, mo~o- and di(lower alkyl)amino, (lower alXylcarbonyl)amino and (aminocarbonyl)amino, while R3 and/or R4 may also be ni~ro; and ~L2~L~39~i R is a member selected from the group consis~g of a radical having the fornlula {~rl A~2 wherein A~l and Ar2 a~e each an aryl radical; a~d a r~dical having the formula - Alk ^Q (b) whe re~rl Alk i an alkanediyl radioal or a lower alke~ediyl radical>
said lower alka~ediyl radical being optionally substi-tut~d by a hydroxy- or a lower alkyl radical; and Q is a member selscted from ~e group consistiIlg of aryl, aryloxy, di~rylmethoxy, Z,2-diarylethenyl, diaryl-me~ylcarbonyl, aryloarbonyl, mono- and dia-yl-ami~ocarbonyl, diaryl~nethyl, the methyl moiet~r in said diarylmethyl group being optio~aLly substi~ted wi~h a cyano-, an aminocarbonyl-, a mono- or di-1 S lowe r al~rlami~ocarbonyl - or a lowe r alkyloxy -carbonyl radical, arylamino, said amino moiety being optionally substib~tedwitha3~aryl, arylcarbonyl-, alower alkylearbonyl-, a~ arylsulfonyl- or a lower all~yl-sulfonyl radical, Z, 3 -dihydro-Z ooxo~l H-benzimidazol-zo l-yl, being optionally 3ubsi~ ted in the ;- or 6-po~ition by halo, l OH phenothiaz~ -10 -ylcarbonyl, being optionally substituted by a halo atorn, 1, 2, 3, 6 tetrahydro-l, 3 -dimethyl~2, 6-dioxo-7H-pur~-7 -yl, 1 -aryl-l, 3 -dihydroisobenæofuran-l -yl, and 2, 2 -Z5 diaryl-l, 3 -dioxolan-4-yl;

12~L~3~S
-wherein aryl is a menlber ~elected from the group co~si~ting of phenyl, substituted phenyl, naphthalenyl, thienyl and pyridinyl, said substituted phenyl having fronn 1 to 2 substituent3, eac~
i~dependently sel~cted from ~e group consisting of halo and 5 (halo-~ubsti~uted phenyl)carbonyl.

Ir~ the foregoi~g definitions the term halo i9 generic to fluoro, chloro, bromo and iodo; the term "lower alkyl" is meant to include straigth and branched saturated hydrocarbon radicals ha~ g from 1 to 6 carbon atoms, such as, for example, methyl, ethyl, 1 -mel~yl-10 ethyl, I,1-dirnethyle~hyl, propyl, butyl, pentyl, hexyl and ~e like;
"lower alkanediyl", a~ used in the definition of Alk, comprise~
~traight and branched alkanediyl chains ha~i~g from 1 to 6 carbon atoms; and "lower alkenediyl't, as used in the definition of AlX, co~nprlses straight a~d branched alkenediyl chains havi~g from 15 2 to 6 sarboIl atoms.

Preferred compounds within the Lnvention are those wherein R is a radical of formula (b) wherein Q is diarylmethyl and Alk is a 1, 3 -propanediyl radical .

Especially preferred compounds within the invention are ZO thoRe wherein R i9 a radical of formula (b), wherein Q is diaryl-methyl and Al~ is 1,3-propanediyl, X is aminocarbonyl, m is 1, and Rl and R2 are both hydrogen.

The most preferred compounds within the inve~tion are selected from t~e group consisti~g of 3-(aminocarbonyl~-4-~,4-25 bis(4-fluorophenyl)butyl7 -N-(2, 6 dichlorophenyl)-l -piperazine-acetamide, the stereochemically isomeric forms and ths pharIna-ceutically acceptable acid addition salts thereoI.

~2~S~3~i ;

The compounds of forrnula (I) can generally be prepared by the N-allcylation reaction of an appropriately substituted piperazine of formula (II) with a reagent af formula (III3 or by the N-alkylation reaction of an appropriately subs~dtuted piperazine of fo:rmula (IV) with a reagent of formula (V). 3 X O
R-W ~ HN/t\N-CH2 -C-N~R
(III) \~/R \~E.5 \~

(II) (I) R-N NE + W_C H_C_/1~134 m 2m (r~) (V) In the above reaotion scheme R, R, R, R3, R4, R, ~n and X are as pre~iously de icribed and W represent~ a reactive leaving group such a~, for example, halo, e. g., chloro, bromo and iodo, or a sulfollylo~y group, e. g., methylsulfonyloxy, 4-methylphenyl-10 sulfonyloxy and the like.

The N-alkylation reaction of (II) ~ith (III) and (IV) with (V) may generally be carried out in a suitable reaction-inert solvent such as, for example, a lower alkanol, e. g., methanol, ethanol, propanol, butanol and the liXe alkanols; an aromalic hydrocarbon, 15 e. g., benzene, methylbenzene, dirnethylbens~ene, and the like:
an ether, e.g., 1,4-dioxane, l,l'-oxybispropane and the like; a keto~e, e.g., 4-methyl-2-pentanone; N,N-dimethylformamide;
nitrobenzene; and the like or a mixture a~ such ~al~re~Lts.

3~S

The presence of an appropriate base such a.e, for example, an al~ali or earth alkaline metal carbonate or hydrogen carbonate, e. g., potassium carbonate, sodium hydrogen carbonate and ~e like, an amine, e.g., N,N-diethylethan?mine and th0 like, pyridine and the like, may be advantageous to pick up ~he acid which ie liberated during the course of the reaction.
When W i9 other than an iodide radical, the presence of a small amount of an appropriate alkali or ear~ alkaline metal iodide, e. g., sodium iodide or pota~sium iodide, may act as a reactio~
promotor. Somewhat elevated temperatures are appropriate to enhance the rate of the reaction and, preferably, the reaction is carried out at ~e reflux temperature of ~he reaction mixture.
The compounds of formula (I) may also ge~;erally be prepared by reacting a piperazine of formula (II), re~pecti~ely a piperazi~e of formula (IV), with the corre~ponding carbonyl-oxidated form of the reagent of formula (III), respec'd~rely (V),following art-known reducti~re amination procedures, i. e. by stirring and, if de~ired, heating the reac~ants together i~ a suitable reductive medi~n, e. g., under catalytic hydroge3:~ation circumqta~ces.
The compounds of formula (I) can also be prepared by stirring and heat~g an amide of formula (VI) wi~h an appropriately substituted benzene deriva~cive of formula (VII) in a suit~ble reaction-inert solvent, if desi~ed, in the prese~ce o:~ an appropriate catalyst such as., for e~cample, a cuprous chloride, boron trifluoride and the like.

R-N N-C H o5_N ~ W~,~4 ~ (I) y_~ m 2m ` R2 \=~
Rl (VI) (VII) R

)395 The compounds of formula (I) can also be prepared by the reaction of a carboxylic acid derivative of forrnula (VIII), where~
R6 i hydroxy, lower alkyloxy, aryloxy, amino, chloro, bromo or iodo, with an ami:cLe of formula (IX) by stirring and, if tesired, S ~eat:ing the reac~ant~ together in a suitable solvent such as, for example , an alkanol , e . g ., me thanol , e~anol arLd the like ; an ether, eOg., 1,4-dioxane, tetrahydrofuran and the li~ce; N,N^
dimethylformamide; 4-methyl~2-pentanone a~d ~e lika.

R-7~N~CmH2m~C~R I 2~ (I) (VIII) (:~) The compounds of formula (I) can e~ren o be prepared by 10 N-alkyla~dng a diamine of formula (X) with a reagent of formula (XI) or by N-alkylat:ing a diamine of ~ormula ~XII) with a reagent of formula (XIII~ following the same procedure as previously described for the reac'don of (II) with (III).
In the followir~g reaction-scheme the 1, 2-ethanediyl radical 15 in (X) or ~XI) and in (XJI) or (XIII) is su~stituted with a radical having the mea~ng of Rl . R3 R-NH-cHz-cH2-N;H-cmHzm C 1 4~R IC~2 CH X

(I) R-NH-CHTCH-WH-CmHzm-C- ~RS W W' (XII) (XIII) ~2~ 3~S
In (XI) and (XilI) W' has the ~ame meaning a3 previou~ly described for W.
T~e compouIlds of formula (I) can al~o be prepared by the ~-alkylation reaction of an a~Line of for~ula (XI~) with an amine o~
5 formula (XV) or by the N-alkylation react:ion of an amine of for~nula (XVI) with an amine of formula (XVII) follow~:ng the same procedure as describe~ hereinabove for the rea::~ion of (II) wi~h (III).

R- ~ ~2N-C H2 -C~N~R~ ~

(XI~) (X~) (I) R }~2 ~tJN C=~}~2m C

(XVI~ ~XVII) Depending upon the nature of X the compounds of for~ula (I) carL ~e co.~r~rted ~:Lto each other following art-know~l procedures of 10 functional grouptra~formations.
Some functional grou};tran ormations ars illustrat2~d in sche~e 1 wherein the radical I R3 R_~-CmH2m 7~R

Rl R2 R5 i3 represented by D.

lL2~ 3~

,_ o ~1 \ \~

\ ;, ~ 3 3 ~ ~
, _ __~; ~Z
O O O
t~) U t.) a ~ ~

~ f a a .. Ul .

33~

The carboxylic unction may be converted il?.to an ester func :ion or an amide func~on following art-known procedures, e.g., by ~tirrino and, if desired, heating the s~cartlng carboxylic acid with an apprc-priatealcohoL re~pec~:ively, an appro~riate amine. The carboxylic 5 acid function may also be cor~rerted irlto an e~ter fur~ctio~ by reacting the s1:ar~dng carboxylic acid with an appropriate alkyl halide in the presence of a ba~e, e. g., 90tium methoxide and the like.
The ester unc~don and the amide ~unc~don may be converted into a carboxylic acid furLction by stirrirlg and, if desired, heating the 10 starting amide or ecter i~to acidic~ or alkaline aql~eous ~edi~m.
Th~ ester func~don may be converted into a~ amide function by s~rring and, if desired, hea~g the starting e~ter in the presence of a~ appropriate ami~e in a sui~;able reaction-inert 301vent.
The aminocarbonyl ~anction may be con~erted into a mono- or di~
15 (lower al~cyl)ami~ocarbonyl function and a lower alk~lam~ocarbonyl furLction may be co~verted into a di(lower al~cyl)a~ninocarb~nyi furlction by stirring and, if desired, headng the ~tar~ng aminocar-bonyl compound, respec~vely, lower alkylaminocarbonyl compound, wi~ a;l appropriate lower alkyl halide following art~ own N-alkyl-20 ating procedures.The carbox~lic aci~ funct~on a~d the ester furLction may be converted into an alcohol func~do~ follow~g art-known reduction procedures such a-~, for example, wi~ metal hydrides, diborane and the liXe.
The alcohol func~don can be conve-ted i~to a carboxylic acid fu.nc~:ion 2S folloc~g art-known alcohol-to carbo~ylic acid oxidizs~g procedures, e. g., with potassium permanganate, chromic trioxide, silver oxide and the like.
The alcohol function can be con~rerted into an ether function follo~ring art-known procedures, e. g., by reactin~ the starting alcohol with 30 an appropriate alkyl halide in ~e presence of a suiable base such as sodium hydride and ~e like in a suitabl0 reacticrl-inert 301vent.
The ether unction can be converted into an alcohol func'don followin~
art-known e~her-cleavage procedures, e.g., by reacting the starlir.g ether with a strong Lewis acid, such a~, for examp}e, boron tri-35 fluoride and the like.

~2~395 Depe~din~ upon ~e nature of R, R, ~2 and R3 the compounds of formula (I) can also be contrerted into each other ~ollowing art-knowr~ procedur2s of funcl:ional grouptranjforrnation. For example, the compounds of formula (I) wherein at lea jt one of R3 and R4 containsa nitroradical~ can be convertedintothe correspondingamine derivatives following art-known nitro-to-amine reducing procedures, g., by catalyt;c reduction in ~e presence of an appropriate cataly~t such a3, for example, platinum^on-charcoal and the like.
The compounds o formul~L (I) ~ay be converted to the thera-peu~cally active non-toxic acid addi~on salt form3 by ~reat;:~ent with an a.ppropriate acid, 3uch a~, for example, an inorg~nie acid, such as hydrohalic acid, e. g., hydrochloric, hydrobromic and the liXe, aIId Rulfuric acid, nitric acid, phoo9phoric acid and t~e like;
or an organ~c acid, ~uch as, for ex~mple, ace~c, prop~noic, 2-hydroxy-acetic, 2-hydroxypropanoic, 2-oxopropanoic, propanedioic.
buELnediois:, (Z)-2^buterledioic, (E)-2-butenedioic, 2-hydroxy-butanedioic9 2, 3 -dihydroæybut~nedioic, 2-hydroxy-l,2,3-propane-tricarbo~ylic, benzoic, 3 -phenyl-2 -propenoic, Q -hydroxyberlzene-acetic9 methanesulfonic, ethanesulfonic, be~zf~esulfonic, 4-methyl-zo benzenesulfonic, cyclohexa~esulfamic, Z-hydroxybe23zoic, 4-amino-2-hydroxybenzoic and the li};e acid~.
C~onver~ely the 3alt form can be con~rerted by treatment with alkali irlto the free ba~e for2n.
It ,~ obvious from ormula (I) that the eompound3 of this invention have at least one aiymmetric carbon atom irl their structure, namely the piperazine carbon atom bearing t~e X-radical. This chiral center may be present ln a R- and a S-configuration, this R- and S-notatio~ being in correspondence with the rule~ described in R. S. Cahr~, C. Ingold and V, :?relog in Angew. Chem. Int. Ed~.
Engl;, 5, 385, ;11 (1~66). Co~ae~uently, the coxnpou~d~ of formula (I) may be prese~t in two different enantiomeric forms, which may be separated from each other, for exa~nple, by con~rerting the mixture of enantiomers ~nto the acid addition salt form thereof with an optically ~cti~Je acid, separating t~e diastereomeric salts, )39S
1~
e. g., by selective crystallization, and liberating the pure enantion~er3 by treatment with alkali.
When R is other than hydrogen and/or the radicals R and C H have one or more additional chiral centers, each of the3e m 2m 5 chiral centers may be present in the R- and the S-conf~guration and the cornpounds of formllla (I) may ha-Je different diastereochemical for~ns, which may be ~eparated from each other by physical separation method~ such as, selective cry~talliza~on and chro~nato-graphic techr~iques, e. g., counter current distribution, colurnn-10 chromatography and the like techniques.
In case Rl is other than hydrogen, the substiblents X and Rmay be ~ttached to the piperazine ring in a cis-relation to each other or in a trans-relation and then compou~ds of formula (I) are nnar~ced as "cisl' respectively "trans".
The co~npound3 of for~nula (I) wherein R is the radical (b) wherein Alk is a lower alkenediyl radical may be characterized by the notat~on "E" and "Z", said E- and Z-notation having the meanings described in J. Org. Chem., 35, 2849-2868 (19~3).
Pure stereochemically isomeric forms may also be derived 20 from the corresponding pure stereoche2nically i~omeric Iorm3 of ~e appropriate ~tarting materials, proYided that t}~e reaction o curs stereospecifically or highly stereose1ectively.
In most compounds and starting materials the stereochemical configuration is not experimentally determined. In those cases it is 25 conventionally agreed to designate the stereochemically isomeric form which is fir t isolated as "A" a~d ~he second a "B", wit~out urther reference to the acb~al ~tereoche~ical configuration.
Stereochemically isomeric forms of the compounds of formula (I) are nah~rally intended to be embraced within the scope of the O i~vention.
A number of the intermediatea and starting materials used in *le foregoing preparations are known compounds, others may be prepared according to art-known methodologiej of preparing ~imilar compounds and for some of t~em synthetic methods are 3 5 pre sented he reinafte r .

V3~t5 The intermediates of formula (II) bearing the X radical i:n the 2-position of the piperazine ring, (Il-a), the intermediates of for~nula (II) beari~g the X radical i~ the 3-position of tl~e pipera-zine ri~g, (II-b), the int~rsnedlates of for~ula (IY) bearing the 5 X radical i~ cr po~ilion of the ~ecorldary ami~e ~ction, (IV-a), ant t:he ~ntermediates of forr~ula (IV), bearing the X radical in the ~ -position of the Recondary amix~e functio~, (IV-b)7 ca~ be derived from an appropriately substi~cuted pipera:Z:lne o~ formula (XVIII~ as represented in ~cheme Z7 whereill pl and p2 represent 10 each a protective group.

N ~H
\~ R2\~R5 ~II a) (IV-a) X~ ~ R3 X

HN N -C: H -G -N ~R4 R -N
~J m 2m 1 \~ \~
Rl 'R R5 Rl (II-~) (rV-b) The ~termediates of formula (Ll-a) and (IV-b) may be derived from (XVIII) by reactirlg th~ la~er with a reagent of formula LW, wherein L is R, respecti~ely Ll, as defined in scheme 2, ~ollow~g art-known N-alkylating procedures as pre~nously described 15 for the preparatio~ of (I) starting rom (II) and (III) and, sub~equently, elimina~dng the protective group pl in the thus obtaine~ (XIX) following art-know~ procedures.

The intPrmediates of formula (II-b) ar~d ~ a) may be derived from (XVIII) by i) protect~ng the secondary amine function with a p2 radical, ii) elimi~ating the protective group pl of the thus obtalaed (XX~, iii) reacting the so formed (XXl) with a reagent of formula LW, whereir~ L i~ Ll, re~pectively R, followi~g art-k~ow~ N-alkylati~g procedure~ a~ previously described for the reactlon of-(II) wi~ (III), and iv) ela~ atirLg the protective group p2 of the thu obl:ained (XXII) following art-known procedures.

Suitable protective groups are/ for exa~nple, optioually ~ub tituted phenylmethyl radicals, optio~ally sub~tituted lower a~yl-15 carbonyl or aryLcarbonyl radicals and ~he like. As can be 3een i~
the reaction~tep (XX) 3~ (XXI) the protec~ive groupq P a~d p2 should be salected so that P ca~ be eliminated without effectiug P .
Sui~a~le protective group~ are, for example, hydrogenolyzable groups as p2 radicaLs, e. g., the phenylmethyl group a~d ~he like, a~d ZO hydrolyzable groups as P radical~, e. g., the trifluoroacetyl group ~d the like.

~2~39~i t~-b) (IV-a) ~\L-Ll ~L=~

p2 -N~l -L

(X~II) ~ I.-W

p2~H (D:-a? (IV-b) ~L~Ll/ L=R
(XXI) \/ elimination X \ / of pl p2_N/~ pl L ~N pl ~ '`~

(XX) \ / (X~

/ ~ L-W

H ~N-P

(X~III) R3 O ,~
Ll CmE~2m-C-~_/ \ R4 Scheme 2 R

33~i The piperazines (XVIII), used as star~ing materials in scheme
2, may be prepared following art..known procedures, For example, the piperazir~es (XVIll) wherein P is a phenylmethyl radical, (XVIII-a), may be prepared, as shown i~:L scheme 3, by r~ac~Lg as appropriately subs~ituted piperazi~e (XXIV') wlth a reagent (XXIII) follow~g art-known y-alkylating procedures as described hereirl-above, or by reacti~g an appropriately substi~ ed piperazi~e (XXIV) with be~zaldehyde following art-knowrl reductive aminatior~ reaction prooedures, i.e., by stirr~g and heat~g the reactants together 1 O in ~he pre sellc e o~ a suitable cat~ lyst, e . g,, platinum -on -cha rcoal, a Sl~ . ble reac~on inert e~olvent under hydrogerL atmosphere.
The starti~g piperazi~es (XXIV) may be derived from the correspo~-dillg pyrazines(XXV)followi~g art-~mown catalytic hydrogenation reac~on procedures or by the hydroge~olysi.~ reaction of ~e 15 cQrresponding di(phenylmethyi)piperaz~es (XXVI), which i~ b~rn may be prepared by reac~ng (XXV~ with (~V~)or (~ X) ~i~
(XXX)followi~g ~e same procedure as pre~ously described for ~e preparatio~ of (I) startir~g from (X) a~d (XI) or (XII) ant (XIII).
In ~5~the 1, 2-etha~ediyl r adical i~l (XXVII~ or (XXVIII) 20 and (XXIX) or (XXX) is substituted with a radicalha~i~g the meani~g o R 1 .

~2~9S

Bz-N NH

(XVIII-a) Bz W / \C H -C}IO
(XXIII)~ \6 5 \ reductive ami3lation reaction X
(X~) HN lYH
R~
(XX~V) j~ \ reductio~

Bz-N N-Bz N
R~/ R 1 (XXVI) (XXV) W-CH~-Cl~-W / \W-C~-CH2-W
(XXVII) / \~YXIX) Bz-N-C~ -CH -N-Bz Bz-N-CHz-C~-N-Bz H 2 Z ~ X

(XXVIII) (X-~) Scheme 3 ~2~3S3S

The i~termediate~ of formula (II-b) and (rV-a) wherein X is a radical of formula ~(CH2) -(CO) -ZH, wherein Z is O or NR, said R bei~g hydroge~ or lower aLIcyl, p is 0 or 1 and q i~ 0 or 1, pro~riaed that the Sllm of p a~d q is 1 and that q is 1 when Z i~ NR7, said i~ter-5 mediates beir~g repre.qented ~y the formulae (II-b-l), re~pectively (IV -a-l ), may also be prepared starting ~rom a piperazine (XX~I) by i) stirring and, if desired, heating (X~XI) a~d a carbonyl deri~rati~re (X~II), whereir~ R a~d R9 are each, independeDtLy from each other, hydrogen or lower alkyl, i~ a ~luitable reac~on-i~ert sol~e~t, 10 e,g, methoxyethanol~dthelike;idesired, inthepre~enceofa suitable base; ii) reacting the t,hu~ obtained (XXXIII) wi~h a reagent of formula LW, wherein L is Ll, or R, following art-known N-al}cylating procedures as previously described or the preparation of (I) starting from (II) and (III); a~d 15 iii) hydrolyz~gOthe t}lUg obtained (XXXIV) in ~cidic a~u~ous mediu~.
(~H;~ )p~ K
HN NH ~R8~ R~
" / ~_ R~
(XXXI) (XXXII ) o ~_~(C~2)p~)q HN N \ /Z

Rl R~8 \R9 N-~lkylatio~L

(XXXIII) S~ O
~CH2 )p ~ (CH2 )p (C )q - ZH
L^N ~ /Z hydrolysi~ ~ L-N NH
7~J R~ `R9 Rl L - Ll (II-b~l ) (XXXIV) L = R (IV-a-l) The in~ermediates of formula (III) ca~l be prepared following the same procedure~ as those described i~:L U. S. Pate~t No.
3,714,159.
The prepaIatior~s of ~e ~termediates of formulae (VI), (VIII), (X), (XII), (XIV) and (XVI) starti~g from (Ill) are ~howz~
in scheme 6.
The intermediates of formula (XIV), (YI), (VIII) a~d (XVI) can be deri~red from (III) by reacting ~e latter with ~e amines (XXXV), respecti~ely (XXXVIII), (XXXI~) and i~H3 ollowi~g art~ 0wn l!~-alkylating procedures a~ described hereinabo~re for the preparatio~ of (I) starti~g from (l:I) aud (II~
The i~er~slediates o~ fo~ula (VI) and (VIII) can also be prepared by the N-alkylato~ reac OD. of (XIV) wi~h an amine of forrnula (XXXVI), re~peo~Yely (XXXVII).
The i:~ter.~ediates of formula (X) ~nd (XII) al:Ld also the inte~ne~
dia~eq o~ for~nula ~V'I) and (VIII) can be prepared by the N~aLXyla~on of (XVI) wi~ (XL), re~pectiYely, (XLI), (XLII) and (XLIII).
In scheme 4 the 1, 2-ethanediyl radical in (XL), (X), (XLI) a~d/or (XII) may be substituted with a radical ha~i~g the meaning of R

3~

2 0 ,~, _ "., X X

~ ~ X X

x x x ~ E ~ z ~ x z ~ ~ y ~ o~
o~ ,=o ~ z z E, E

æ ~ ,'~

o--x~ E E ~ .
x~ ~ _ x ~ ~

~ ~1 ~æ~
+

3~Si The intermediates of forsnula (V) can be prepared by the N-alkylatio~ reaction of an appropriate acid halide (XLIV) with a~
aniline (IX), The ir~tersnediates of formula (XV) a~d (XV:~I) can in h~rn be derived 5 from (V) by reacting the latter wi~h amrnonia, re~pectively an a~nine (XLV ) following art-~nowr~ N allcylating procedurec.

W~ g~hal~ T R2-N~r~3.4 m 2m ~
(XLIV) ~ (IX) R5 W C H C N ~ R4 m ~sn 2 R ` 5 (V~ X
W
jNH3 ~ ~ (Xl.V ) (X~T~ (~VII) The functional grouptransforma~ion prosedure~, as described i~ sch> may also ~e carried out on all the intermediates having the radical X in their structure.

~2~

The compounds o formula (I), their phar~naceutically accep table acld addition salts and the stereoch~mically isomeric ~ormj thereof~ w~en intravenously or orally administered to vertebrates, illcrease the oxygen tensio~ (PO2) Of the coronary sinus ve~ous blood.
5 Said PO2 ~crease is e~ide~ced by the experime~tal data obtair~ed i~ ~e coronary si~us ~renous pO2-test i~ ~e anesthe~zed dog, which is described in The Journal of Pharmacoloay and Expari-rnentai Therapeutics, 15Z, (2), 265~274 (1966).

Coronary sinus ve~oll~ PO2 in the anesthetized dog, A cardiac catheder was advanced into the coronary sir~u~ o~
the anesthetized dog and oxygen te~sion (PO2 in mm Hg) of the venous coronary blood was measured with the Gleichmann-L~bers modi-ficatiorl of the Clark electrode, housed i~ a contant blood flow cuvette.
The PO2 values were read off the cali~rated scale of a light-spot ~al~anometer. Aortic blood pressure, respiratory rate and electro-cardiogram were recorde~l throughout the experiment. The animals breathed ~pa~taneously. Ater a control period of 30 min.
a steady state was usually obtai~Led. At this point a dose of the active 20 compound was ~3iverl by 310w intravenous injection. Subsequent intra-ve~ou~ doRe2 o~ other active compounds were injected at the end of each ~lew steady Rtate period of not less tha~ 10 mi~, Tables 1 and 2 show the lowest effestive i~tra~enous dose (in mg/kg body weight~ whereby the PO2 irL the coronary sinu~ was 25 increased by 100% as compared to the control ~ralrle (colu~sm 1) a~d the duration of ac~ion at said lowe~t effective do~e (column 2) The data, illustrated i~ tables 1 alld 2, are intended to illus-trate and not to limit tha qcope of the present inventio~

~Z~3~5 ;!3 _ ~ ~ _ _ _ _ o - o o _ o o o _ o _ o _ _ o _ i ~ ~ , ~ O O ~ C~' -- O ~ ~1 ~ O C:: ~ O O
O ~ ~) _ ~
, ~ ~ 5L~I;
'~ ~
.,., _ Q ~ ~ ~
. ~ o~ ~ o Q ~4 c .o ~ ~ . ~ . . ~ . . . . . . .
~ a cl c~ ~ o o o c~ _ o ~ o _1 3 _ _ D ~ ~

~ ~ o ~ O ~
td O ~ U ~ ~ n ~2 ~ ~ ~ N ~1 ..... , . ~
.~ ~
to ~0 :~ ~ V ~ ~ ~ V~ U ~ U '~
~. ~ b ~ ~ 1 ,~ C ~ U
æ P~ ~
o~ ~ ~ ~ o u ~ 0 o ~ o o __ ~
~, _,_ xt J ~
~ ~ ~ ~ ~ ~ ~ ~ ~ rJ ~ ~ ~ ~ ~ ~ ~ ~
~ ~ ~ ~ æ ~ x ~
~ o ~ u u ~ v ~ u ~
o ~ ' ~- o ~ ~
z: z ~ z z ~ z z z z o ~ o o o o o o o o o o o o o o u, ~ o u, ~ y ~ o y ~ ~ ~3 .., ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ , __ l l l l l l l l l l l l l l l l l _~ ~ ~ ~ ~ ~ ~ _~ _~
vvou~v~ vuo~uu Y ~ x u v ~ ~ u c) u c) ~ u ~; ~ x ~ -- ~ ~ ~ -~ ~~
l ~ ~ ~
l ~ `4 ~ ~ ~ ~ ~ ~ ~ ~o ~ ~o `
_ rJ U V U U r~) r~ r~ V r~ rJ
,, E~ l ~ ~ r;, ;., ~r;.,~ ,r,~,r,, ~r;, ~
I , , I I I I I I I ~ I I I I I I
~r ~ ~ ~ -- ~ ~ ~r ~r ~ ~ ~ ~ ~r ~ I
_ _ _~_ ~2~3~S

, ~ ~: _ _ o _ _ o o ~ ~ _ _ a~ ~ ~ ~ r- o o ~ _, ~ o ~ o o o co ;~
.",t~
~ _ ~ ~
o ~J _I ~ 1 t~ O
_ _ ~ ,3 --O -- - ~ ~ ~ ~i _ o ~a 1~
~ ~ ~ o o _ _ O ~, o~ o~ o ~ ~---l ~
o ~ o l l ~ l ¢
~

~ ~ ~ y v ~
U d~ ~ ~ W ~ ~ ~ ' l ~
`4 ~ ~ ~ ~ ~ o ~ ~ ~ ~
f~l ~ ~ ~a -:~

'~ q - - l r~l ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ l ~ ~ l z;
o oo o o o o o o o o o o c ~ l o l x ~ v ~ v ~
_ . _ . ~
l ll l l l l l l l l l l l l l l V ~ V ~ U t~V V V ~ U ~J
~ l o ~ X
~ U ~ V
_.~ ~ ~ ~ ~ ~ ~ ~I~ ~ ~ ~ r~ ~ r~

~V ~ ~
~ V ~ tJ ~ t.) U U t,) ~J t~,~ V V t.) V O r~ I
~t t. ~ r;~ t" ~
I I I ~ I ~ ~ I I I I I I ~ I I
~P ~ ~ ~r ~ ~ ~ ~4 ~ -r __ , ~
, , . _ .. _ . . , , , . .. , . . .. . _ ~Z~33~5 z5 _ . ~
, ~ ~ ,. o C~ o ~d C u~ ~ ~ ~ 5 1~ ~ u7 ~ ~ ~ cr~
~:: :~S O
~:: __ ~t~
_~ ~ ., u~
O ~ ~! ~ ~ Ul ~ ~ ~ U~
O _. .~ 3 _ ~ ~ G O O t~ i 0 ~0 _ _ . ~ ~

O
~ ~ v I ~
C b -l ~

:c v u u~ ~ ~ v ~ x v ~ v ~ v v ~ `o ___ - - ~
l~l l U ~ ~ :C X ~ 3 V
_~

Z z ~; z ~ 0~ O o o ~ ~
~ o o o o o ~: o ~ o o o V o ~ .
X V ~ t~ V ~ V U ~ ~ U ~ V ~ ~
I I I ~ I I I ~ I O I I I I ~ I ~ I
U ~ O ~ ~ ' _ . ~ ~ ~ . _ .
I I I I I I I ~ I ~ I I I I I I
~1 ~ ~ ~ ~ ~ ~ ~ _~ _~ r~
o ~ ~ -- $ i ~J V U U V ~ U
1_ 5 ~ -~.) U

V ~;1 0 U (.) ~ O V t~
~`1 r~ J r~ r~ l r~
t~ ~ ~ ~ ~ ~r ~q ~ ~ d' ~ ~ ~ ~ ~ e;~
U ~ y t.) y o o V U O U
l l l l l l l l l l l l ~r ~r ~ ~ ~ ~ ~ ~ ~ _ ~r ~ ~r ~r , lZ1l~3~S

_ _ ~ o o o o U~ ~ o o ~ o o U~ o o ~ h~ ~P ~ ~r ~ 1~1 ~ ~ ~ t`~ ~ r- O` ~
C ~-- , _ . - ~
~ ~ Ln O __ u~ ~ ~ o n ~ ul ~ u~
3 ~ _ _. o ~ o ~, ~ _ ~
~. o _,~ o ,~, o~, tn X
o~ I , , , , I, ,, I ¢ , ~ ~ O
l ~ o ~ %

v v ~ v ~
--# C~ ~ ~# ~ o o ~J ~ ~ ~ ~ `~~ ~ 1 . . , , _~

.. _ ~

r 1 ~ rJ

7 ~ t~ ~ Z 1 Z; ,~,~3 Z Z ~ ~ t~
O ~ O O O 3: :: G O ~ o O
~C ~ V t~
, ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ' _ _ _ _ _ , l l l l l l l l l l l l l t t~ V ~ t~ t~ t~ t t..~ t~ ' ._ .. , O t~ O V U ~ U U
C~ ~ ~ X~
~ ~ V ~ V I
_~

'~ h ~ ~ h ts~
d I I I I I I
'?' ~ ~
_ _ _ ___ _ ____ _ _ _ _~ _ _ , .

(93~S

_ _ . .. _ o ~ o o o o o ~ o o ~ t~ o o o _ o Cl~
~1 C ~ ul r~
h O _ .~ _ __ _ ~.~ ~ ~ ~ o _, ~ 3 c o o ~ ~ o o ~ _ o c~ ~ _ o o l ~r __ ~ . ._._ ____ _ _ ~ ~
O _~
~ qo ~ D r~
11 ~ 0 CO ~ 0 _ ~ 5 .
_l ~, ~ ~ ~ ~Q
O ~ ~- I I I I 1 ~ 1 1 1 1 ~ 1 I
~_ _ I I I I I I r~
~ r~ r ~ r ~
O ~,rr~ V V
' 'I ' ' ` ~ Z ~
rlt ~O ~ ~ V ~ ~ q Y Z
~ U '~ x ~ 3 v ~
V t~ ~ ~ ~ . ~, ~ V ~
~ ~ ~ ~, ~ ~ ~ ~ ~ ~ ~ ' ~ ..
. _ _ ~ ~ ~ 1~ ~ ~I W 1~ ~ ~ ~
.~
1_~
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~`3 d ~
V V V ~ V V V V V V V ~ V,_ . . ~
5 ~ X ~ _ V ~ ~~ ~ O U t~ ~ V ~ ~7 V
o Z ~ Z ~ Z ~ Z ~ Z ~ ~ Z
o ~ o V o o o o o o o o o o o X t~ O V V W O t~ ~ V
l l l l l l l l l l l l l l l ,.
l l l l l l l l l l l l l l l v v o v v '~ 7 o ~
~ v c) ~ v v 'J v v ~ v v ~ ~J v v --~ ~ ~ ~ ~ ~ ~--~ ~ ~
^ ~` ^~r '~ '~P ~ '3' d' ~ ~ _~ ~p --V V ~ V V O V y ~ V O V U U
~:1 r~ r;~ 4 rw r;.~ r;~
l l l l l l l l l l l l l l l , _... _ .. ~ ~

" ~L;2~V39~i _ _ __ ~
~
~,, o ~ o ~ o o C~ -o o ~ o ~o o ~ _, _ ~ ,,, ~,.~
.!~ 3 ~
1~ ~ `O ~ ~ o ~ o ~
_, ~ :: ~ o ~ ' o ._ c~
~ Z
_ _ --~ ~ ~ X~ 0 3' 0 ~ ~d o ~ Ul~ ~ ~ r~
_~
~
o ~ , , . ,, , , ~ ,,~
:~ ~ o o , , , , , ~ ,- y '~, z ~ o ~ o ~ x ~ v v ~ ~o ~ ~o ~ u ~ x '~
~ l l l l l l ~--- ~ ~o ~ ~ ~
J
~ - ~

~c ~ o ~ o o ~ y ~ o u ~

~o ~
d ,, h ~, ~ ~ ~ ~ ~ _ O ~
O ~ V 14 '~ ~ V ~ U
~a o ~o ~ ~ O V /Z;~ ~ O O V
R ~ h ~ ~
P , . ~ ,--~ ~ =

~2~1~3~fi~

_~
g .,. o 1 U O d' g ~ ~ O U~ n o ~ ~t A /\
O
~ S
._ ~ 3 ~o ~o ~ ~ ~ ~ ~ n O ~ ~ ~ ~ O
o o o o o o ~ o _. ~ _, ~- ~ o o I ~ o 3, ~ ~
~ o ~ V V V O V
_ ~ ~ ~ X
~ ~ -- ,:
''o .
o t~

~ ~ v ~ ~
~ u y ~ ~ t~ d~ d' ~ ~ ~ ~ ~ ~
-l ~ x ~
- ~
~ ~ x z z ~
~ o o o o o o o o o o o o y y ~ u y t, u y t~
~ r~ ~ ~ ~ ~ ~ ~ ~ ~ ~
l ~
d~
~1 ~) U ~ V ~.) 1~ ~, ~.) ~ ~ b O ~ G _ t.~ ~.) O V O ~
t~ V
t~
~=
~ __ __ ... . . ..

l'he compo?lnds of formula (I), their pharma~-eutically accep-t;Lble acid addi~don salts and the stereochemically isomeric forms thereof, ad~ninistered i~travenously or orally, also exert a protective ac~orL again~t the conseque~ces OI co~nplete normothermic ischa.emia i~ dog hearts. The test, evidencing said protection, is described i~ "Myocardial ~rotection a~d Exerci e Tolerance: the Role of Lidof3.aæine, a New Anti-anginal Agent.", Royal Societ~r of Medecine Inter~ational (;o~gress a~d Sy~npo~ n Serie~ No. 29, p. 89-95 (1~80).
.

Experiments were performed on adult anesthetized beagles wil:h a body weiglt ranging between 9 a~d 15 kg.
Sy temic blood pressure was measured~ia the left: femoral artery, us~g a J:F Millar ~p manometer. A Swann-GarLz thermo-til-~tio~ catheterwa3 i~sertedvia the right femoral vein and placed 15 iD lhe pulmonary artery to measure cardiac output by thermodilutlo~
and central nervous pressure through ~e prox~mal lumen. The other femoral ~einwascannulatedtofacilitatel:he injection of saline at room temperature. The right femoral artery was cannulatedand con-nected to the arterial line of ~he cardiopulmonarybypass. The heart 20 was exposed througharigh~thoracotomy and suspe~ded in ~ peri-c~ rdial cradle . The right atrium was ca~nulated f or c onnec t.on of the venous 17 0 of the heart lurLg macl1ine. Left ventriCl?lar pressure was measured after insertion of a JF Millar tip mano~neter via p-~-monary vein.
z5 For cardiopulmonary bypass, two occlusive roller pum?s, a bubble oxygenator and a heat exchangerwere used The he~rt lung machi~2 was primedwith 2000 ml of fresh hepar~ized blood, obtained from a donor dog, Serial blood samples were taken duxing the experiment for monitoring pOz, pCOz a~d pH. The left ~rentricle was 30 vented through an apex cannula at the sl;art o t}le coronary bypass, during ischaemic: arrest, and throughout the subsequerLt 30 m~nutes reperfu~ion period ..... .. .. . . . .

~2~

Tl~e experimental de~ion:
~=
Approximately twenty flve minutes after i~travenous admini-stration of the active compou~d, the animal was subjectedto total cardiopulmorlary bypass at 37~C by clampi~g the ascen-din~ aorta for 60 minutea. ~t ~e begi~ni~g of the complete ischaemia an amount of the acti~re compound~wa~addedtothe whole blood content. During the fuIl period of complete ischaemia, myocardial temperature was kept constaDt at 37C.
Whilst the heart was empty and at re s~ the coronary artery was reperfused for 30 minute~. After I0 minutes of reperfusion, ehe hea~twasdefibrillated At th2 end of the reperfu~ion period, the dog was weanedfromt~e cardiopulmonary by~as~ and uactional parameters were recorded until the end of the expe rime~Lt.
Table 3. column 1 shows the lovJest e~ective intra~re~lous dose ma/kg body weight) of the compou~d whereby the heart of the dog retook his normal functiotls after 60 minu~es of complete ischaemia, while colum~ 2 ~hows t~e total amourlt of the con~pound, added to ~e whole blood cor~tent.

The e:~perimental procedureq were th~ same as described for the intraver~o~s route of administra~on~ except that the ac~ve co~npou~Ld was administered orally and neither ~iven intra-venously rLor added to the whole blood conte~t.
Table 3, column 3, shows the lowest effec~ive oral dose (i~
m~/kg body weight) of the compotmd whereby the hea.t of the dog retook its normal fu~ction~ after 60 minutes of co~nplete ischaer~ia .
3~ The data, illustrat2d in table 3, are intended to illustrate and not to limit the scope o~ the present invention.

31 2~f~3~5 ~", 3 ul ô , U~

~ E _ _______ h ~3 9 Ir~ ~ O L~ ~
U ~

C~=L) _ ~3 ~ o o J E ___ V~, ~o ~o ~~ ~o o~o ~ ~ ~ V V ~ ~

~ X~

~I x z O O o a~
V
_ _ ~;~lV3~5 1~ view of their pharmacologiçal acti~ities ~e compourlds of formula (I) are useful to ameliorate the blood perfusion of the rnus-cular ~ssues of the heart and also to protect the heart, partially or completely, from myocardiaL injury caused by more or less briei~
5 episodes of ischaemia, anoxia or hypoxia and, as 3uch, the subject compounds ~nay, for example, be used ~ ths cure or the prophyl-axis of patients suffe~ing from angina pectori3 ar~d of patient-q ~ a pre or post myocard i~farct ~tage by administerirLg said compounds intravenously or orally.
The subject compou~d~ may be formulated i~to ~rarious pharm~-ceutical forms for admLi~:Lstration purpo3es. To prepare the pharma-ceutical composilio~s of this inventis:~, an effectivs amount o~ the par-ticular compound, i~ ba e or acid-a~dition salt orm, as the active i~gredient is combined in int~ate admixhlre wi~h a pha~n3aceutically 15 cceptable carrier, whioh carrier may take a wide variety OI for;ns depending on the form of preparatior~ desired for adrnirListration.
These pharmaceutical compositions are desirable in unit3ry dosage ~orm ~uitable, preferably, for administra~on orally, rectally or by pareQteral injection. For exa~ple, in preparing the composi 20 tions ~ oral dosage form, a~ly of the usual ph~rmaceu,rical media may be employed. such as, for e~ample, water, glycols, oils, alcoholq a;~d the like ~n the case of oral liquid preparations such as suspension3, syrups, elixirs a~d solutions; or solid carriers such as staxches, sugars, kaolin, lubricants, binders, disi~tegrating agent~
25 and the like in the case of powders, pills, capsules and tablets.
Because of their ease i~ admiNstralion, tablet and capsules repre-sent the most ad~rantageous oral dosage u~it form, in which case solid pha~naceutical carriers are ob~ously employed. For parenteral compositions, the carrier will usually comprise sterile water, at 30 least in large p~rt, thou~h other ingredients, for example, to aid solub;lity, may be included. Injectable solution, for example, may be prepared in which the carrier oomprise3 saline solution, glucose solution or a mLxture of saline and glucose 301ution. Injectable sus-pensions may also be prepared in which case appropriate liauid ~2~3~

carrier, suspending agents and the like may be emp~oyed. Acid addition 3alts of (I), due to their increased water solubility o~rer the corre~ponding bace forT~, are obviously more suitable in ~he preparation of aqueou~ compositions.
It i~ ~specially advantageous to formulate the aforenlentioned pha~maceu~cal compositions in dosage unit form for ease of ad-ministra~on and uniformity of dosage. Dosage unit form as used in th~ speciication and claim~ herci.n refers to physically discrete unit~ suitahle a~ unitary dosagee, each u~t contal~g a prede-termined quantit~ of ac~ve i~agredient calculated to produce the de~ired therapeutic effect in associaiion wi~ the reqllired pharma-ceutical carrier. Example of such do~age UIlit forms are tablets (i~cluding scored or coatet tablet3), cap~ule~, pills, pawder pacXet, wafers, injectable solutions or suspension~, teaspoonfuls, table-15~ spoonfuls and the like, and segr0gated rnultiples th~reof.
~he following for;slulations exemplify ~pical pharmaceutical co2~npositioIls i~ dosage unit form suitable for systemic ad~inistration to patients i~ accordance ~nth the preserlt i~vention.

~æ l~e followi2lg forrnulatio~L pro~des 10 lit~rq of an oral-drop solu~on comprising 5 milligrams of 3-(aminoca~bonyl)- ~, 4-bis(4-:~uorophe~yl)buty~7-N-(2, 6-dichlorophenyl)~l-piperaz~e-ace~ mide as ~e ac~e Lngredientper ml.
A.I. ~ - 50 grams 2-Hydroxy~ropa~oic acid ~ 2.5 milliliters ~Iethyl 4-hydroxyber~zoate --- --- -- ---~ 18 ~rams Propyl ~-hydroxybenzoate --------------- 2 grams Pyrogen-free water q. 5 . ad lOliters.
The r~ethyl and propyl 4-hydro2yben~oates were dissolved in about 5 liter3 of boiling pyrogen-free water. After cooling to about 30 50C there were addedwhile stirr~ng the 2-h~droxypropanoic acid and thereafter the ~.I.. The solutionwascooledtoroom temperature and supplemented with pyrogen-free water ad ~rolume. The 901utionwas sterilized by filtration (U . S . P. XVII p. 311 ) and filled in steril~
C ontaine r S .

~Z~L~3~3: S
~= The oral drop solutiorl described herebefore may be used as an injectable solution.

Ca~sules: 10, 000 Hart gelati~e capsules, each containing as the ac~ve i:~lgredient (A.I.) 20 milligrams of 3-(arninocarbonyl)- -~,4-bi (4-~luorophe~yl)buty~7-N-(2, 6-dichlorophenyl)-1 -piperazine-acetamide ,were prepared f:rom the ~ollow~ng eomposition:
A.I. -~ - 200 grams Lactose ------~ - 1000 granns 5~rch ~ O-- 300 gram Talc ------------------------------ 300 grams ~alcium stearate -~ -~ 10 granns An u~iform ~ture of the ac~i~re a~d suppleme~tary ingre-dient3waspreparedandfilledinto two-piece hard gelat~e capsules.

Tablets: 5000 Compre~ssed tablets, each co~tai~ng as the active ___ ingredie~t (A.I.) 25 milligra~s of 3-(aminocarbonyl)-4-/~,4-bis(a^
orophenyl)buty~7-N- (2, 6-dichlGrophenyl)-l-piE~erazineacetamide, werepreparedfromthe follo~i~g fors~ulatioIl.
A.I. ~ ----- 125 grams S~rch ---~ 150 grams Dibasic calciunn pho3phate hydrous ~--~------~--~-------~-------- 6~0 grams Calciu~ stearate - -~----------------- 3i grams The finely powdered i~gredie~tsweremixedwelland granu-lated with 10~'o starch past2. The granulationwasdriedand compres-25 sed into 9:ablets.

Oral sus~ension: :The following for~nulation provides S liters of anoral susper~sion comprising as an active ingredient (A. I. ) l; milli-grams of 3 - (aminocarbonyl) -4 -~4, 4 -bis (4 -fluorophenyl)buty~7-N -(2, 6-dichlorophenyl)-1 ~piperazineacetamide per teaspoonfull 3 0 ( 5 -millilite r g ) .

395i A.I. ------------------- ----------- 15,0 grams Sucrose ~ 300.0 grams Dioc~lsodium sulfosucc~ate--~------ O.5 grams Be~onite -~ - 22.5 gram~
~e~ylparabe~ -~------------------- 7.5 g~ams Propyl paraben ---~ ---1.5 grams A~tifoam A. F. Emulsion ---~ 0.15 grams Propylene Glycol -----~ -52.0 grams FD&~ Ye~ow ~ 5 --~ -0,1 g~ams Sodiun~ cyclamate ~ ^50.0 grams Sodiurn ~acchar~n ~ --;.O grams Ora~ge Flavor ----------~ 7.5 gram~
F~ered puri~ed water, ~.s., ad 5lit~rs.
The parabe~s were ti~solved i~ the propylene glycol andthis 15 501utio~ was added to a solutio~ o~ the sodium cyclamate, sodium sac:charin and sucrose in half the wate~: The bentonite was suspended i~ hot (about 85C) water and stirred for 60 minutes The be~tonite ~olu-tion waa zdded to the former solutio~L The sulfo~uccinate wai dis~olved in ~ome water and the A, L was susper~ted irL the resulting solution.
20 The A~tifoam A. F. ~ulsion which was diluted to a lotion con~istency with a minimum ~mourlt of water was added a~d mlxed well. The latter suspe~sion of A. T was added to the former mixture and mixed well.
Then the E~D&C Yellow*~ 5 di~olved in a small amou~t of water wa~
added, ~followed b~ the addition of orange fla~or a~d q. s. to ~rolume 25 with water. The whole w~s stirred to a homogeneous mi.xture. The mL~ure was passed throuah a colloid mill and filled into suit~.ble con-tainer s, I~ ~iew of the pharmaceutical acti~ty of the subjeot con~pounds, it is e~tent that the pre en~ ~vention pro~rides a method of amelio_ 30 rating the blo~d perfusion of the muscular tissues o ~he heart and also a method of protecting the heart from myoc~rdial i:r~jury caused by more or less brief episode~ of ischaemia, anoxia or hypo~na, by the systemic admir~is~ration of an effecti~te amount of a compound of formula (I), its pharmaceutically acceptabla acid addition : .

)3{~

salt or a stereochemically iso~neric form thereof in admix~ure with a pharmaceutical carrier.

The following example3 are i~lte~ded to illustrate but ~o~
to limit the scope of the present inve~tion. U~less otherwise stated 5 all parts t~erein are by weight.

~2~ S
3~
EXAMPLES

Example I
A mixture of 20 parts of 2-chloroetha~lol, 3 par1:s of slltfuric acid a~d 16 parts of benzene was heated on a water-bath. The~ there 5 were added dropwise 35 part~ of 4-fluoro-a-(4-fluorophenyl)benzene-methanol dissolved in 32 parts of benzene, A~ter the addition was complete, ~he whole wa~ stirred and refluxed for 4 hours. Ater cooli~g the rea. ~ion mixture was poured into water, The benzelle layer wai separa~ed9 dried over calcium chloride and evaporated.
10 The residue was distilled i~ vacuo, yieldiIlg 35 part~ of 1, 1 '-LT2-chloroethoxy)methylene~bisL4-fluorobenzene7; bp. 164-16bC at 1. 5 mm. pre~ure; nD~ 462; d20: l. 2290 (in~ermediate l).
Example II
Through a s~irred mixture OI 11. 7 parts of (i-fluo~o-Z-hydroxy-15 phenyl)(~-fluorophenyl)methanone a~ld 45 parts of N,y-dimethyl-forma~ide nitrogen wao bubbled while cooling at abou~ 5~G (ice-bath).
Then there were added portionwi~e 2. 4 parts of sodium hydride disper~ion 50%: heavy fo~uni~goccurred Uponcomple~ion~ there were added 23. 6 parts of 1 -bromoa3-chloropTop ne while still cooling at 20 5C. $he whole wa~ he ~ed to gO'C: a;nd ~tirTir:Lg at thii temperature was co:nti~ued for one hour. After cooling to 5C, the reaction mixture was poured o~to 400 part~ of water and the product was e~ctracted twice with 180 parts of benzene. The extract was d~ied, filtered and evaporated. The re idue was purified by colum~-25 chromatography over ~ilica gel u~ing trichlorometha~e as eluent.The pure fractions were collected and l:he elue~ was evapora~ed.
The re~idue solidified on triturating il:L petroleume~her. After cooling to 0C, the product wa~ filtered off and dried, yielding 10.7 parts (69%) of /2-(3-chloropropoxy)-5-fluoropheny~7(4-fluoro-3 0 phenyl)methanone; mp. ~0 C (~termediate 2 ).

Example llI
A m~xture of 16 parts of 1 -cyclopropyl-2, 2-diphenylethanone and 300 parts o hydrochloric acid were ~tirred and refluxed for
4 hours. The reaction mi~ture was cooled and extracted with
5 2, 2l-oxybispropane. The extract wa~ washed with water and with a diluted sodium hydrogen carbonate solution, dried, filtered and e~aporated9 yield~g 17 part~ of 5-chloro-1,1-diphenyl-2-penta~one as a residue. (i~termediate 3).
Exa~nple IV
To a ~tirred ~olution of 21. 9 part~ of 4-fluoro-a ~(4-fluoro-phe~yl)be~ze~e~ethanasni~e in l 60 par~s of 2~propa~one were added 11. 66 parts of sodium carbonate. Then there were added dropwise 12. 43 part~ of 2-chloro~cetyl chloride ~t a temperature below 30t;
(coolang in a~ ice-bath was nece sary). Upo2l cor:npletio~, ~tirr~ng was continued first for one hour at room temperature and further ~or 2 hour~ at reflux. After cooling to room temperature, the sodiurn carbonate wa9 filtered o~ and washed with Z-propa~one.
The filtrate was evaporated and t~e residue was cry~talli~ed from 2,2'~oxybi~propalle, yieldi~g 20. 6 part~ of N-Ci~(4-fluorophenyl)-methyl7-2-chloroacetamide; mp. 127. 6C. (intermediate ~).
Example V
To a stirred soluti~ of 10. 6 parts of N-(4~fluorophenyl)-4-methylben~erlesulfor~amide in 68 parts o N,N-dimethylforrnamide were added portionwise Z. 1 parts of a sodium hydride disper~ion 50%:
temp. rises to 35C. After stirr~g for 20 mi~utes, the whole was cooled in an ice-~ath (about 15C) and 12. 6 parts of l-1aromo-3-chloropropane were added quickly. Stirring was cont~ued fir t for 20 minute~ at room temperature, the~ for 3 hou~3 at ~t5C a~d further o~er;Light at room temperature. The ~eaction mixture was poured onto ice-water a~d the product was extracted with methyl-benzene. The extract was washed three times with water, dried, filtered and evaporated. The residue was cryst~llized from petroleum-ether, The product was filtered of:E a~d recrystallized from 2, 2' -oxy bispropane, yieldi~g ll. 37 parts (83, Z%) of N-~3 chloropropyl)-N-(4-fluorophenyl)~4-methylbenzene~ulfonamide (intermediate 5).

359~
~o Followi~g th0 same proced~e and ~tarting from 4-fluoro-N-(4-fluorophenyl)ben~amide there was al o prepared:
N-(3-chloropropyl)~-fluoro-N-(4-~luorophenyl)berlzamide a~ a residue (intermediate b).
5 ~I
To a stirred mix~ure of 25 par~ of 1, 3~i~obenzofurarLdione a:nd 108. 5 parts of fluorobenzene were added portio~wi e 50 part3 of alumi:nium chloride, Up~n comple~io:n, the whole was heated 910wly to reflux a~d sti2ring wa~ co~tinued for 1. 50 hours at re~lux 10 temperature. The reaction m~t~e was cooled and pou:red onto a mixture o~ cru hed ice a3~d 60 parts of co~cerL~rated ~ydrochloric acid.
The produst wa~ extracted twioe with dic}llorometha~e. The combiIled extsact~ were waYhed with a sodium hydroxide 301ution 10%. The aqueou~ pha~e was eparated, wa hed with 2, 2'-oxybi~propa~e a~d 15 acidified with c:oncentrated hydrochloric acid while cooling. The whole was stirred for one hou~ at room temperature. The precipitated product wa~ filtered off and dissolved irL benzene. The solution was distilled azeotropically to dry. The solid residue wa stirred i~
hexa~e, The product was filtered o~f and dried iD vacuo at aboul:
~0 50C, yielding 33. 5 part3 (80. 7%) of 2-(4-nuorobe~zoyl)benzoic acid; mp. 129. 2C (intermediate 7).
To 1190 parts of l,l'-oxybi~etharle were added at o~ce 50 part~
o~ lithium aluminium hydride. Then there was dded dropw;se a solutio3l of 213. 7 part~ of 2-(4-fluorobenzoyl)be~zoic acid i~ 87~
25 part3 of 1, 1 '-o~ybi~ethane ~o that the snixture was kep~ at reflux temperatu~e. Up~ completion, stisri~lg was continued first for 30 mi~ute a1: room temperatu~eO the~ for 2 hours at reflux and fur~her overnigh~ at room temperature. The reaction mixture wa~ cooled to 0C arLd there were added dropwise $uccessively 50 parts of water, 30 50 part3 of a 15% Rodillm hydroxide solution and 150 parts o water all at 0G, The reaction mixture wa3 filt2red over Hyflo and washed thoroughly with 1,1 '-oxybisethane. The organic pha~e was separated washed with water, dried, filtered and evaporated. The residue was f~
*Trademark ~2~ 5 wa~ crystallized from a mixture of benzene a~d hexane, yieldi~g 170, 4 part~ of a ~(4-fluorophe~yl)-l, 2-be~zenedimethanol; mp.
+ 75C (intermediate 8).
A mixture of 200 part3 o~ a-(4-fluoropherLy1)-l, 2-ben~enedi-methanol a~d 2295 parts of phosphoric acid 60% was stirred for 3 hours at 100C, Stirri~lg wa~ co~ti~ued overnight at room temperature. The reactioll mixture was polLred orlto wa~er and the product wa~ extracted twice with 1,1 '-oxybisethane, The combined ea~tract~ were washed with water, with a 10 % ~odium carbo~ate aolutio~ and aga~ with water, dried, filtersd a~d evaporated.
The re idue was distilled, yieldi~g 57 parts of 1-(4-fluorophe~yl)-1,3-dihydroisobenzqfuran; bp. 108C at 0. 2 mm. pressure ~ termediate 9)0 Example VII
To a stirred and cooled (2-propa~orle/C;02-bath) amou~t of 1080 parts of ammonia was added 1 part of iro~ (III)chloride, followed by the p~rtionwise additioll of 7. 7 part~ of sodium urLder nitrogen atmosphere. A~ter stirrirLg for 20 mi~utes, there was added dropwise a so~uti~ of 64. 5 part~ of 1 -~4-fluorophenyl)-1, 3 ~dihydro~
isoDenzofuran in 105 part~ of 1, l'-oxybisethane while still cool~g.
Then there was added d:ropwise a solution of 75 part3 of 2-(3-bromo propoxy)tetrahydro-2H-pyran in 37 parts of 1,1 -oxybi jethane.
Up~n completion, stirring ~.va c~ti~ued for 2 hours under nitrogen atmosphere in a 2-prop~one/C02-bath. Without cooli~g and without nitrogen, there were added dropwi~e ~lowly 190 part3 of 1, l '-oxy-biqethane and stirring was co~tinued overnight at room temperature.
225 Part3 o~ a ~aturate ammo~ium chloride ~olution were added dropwi~e followed by the addition Qf 200 parts of wa~er, The layer~
were ~eparated a~d the aqueous phase was extrac~ed twice with 1, 1 '-oxybi~etha:E~e. The comb~ed organie phases were wa3hed with water, dried, fil~ered a~d evaporated. The residue wa~ purifed by colu~n-chrornatography over siliea gel u~ing a mLxtu~e of trichloro-metha~e and methanol (99. 5:0, 5 by volume) as eluent. The secondfrac-tionwas so llected and the eluentwas evaporated, yielding 32 6 part3 of 1 -(4-fluorophe~yl)-1, 3-dihydro-1-~3-(tetrahydro-2H-pyran-2-yl-oxy)propy~7isobenzofuran as a residue (intermediate 10) 39 6 Parts of 1 -(4-fluorophenyl~-1, 3-dihydro-1 -~3-(tetrahydro-2H pyran 2-ylo~y)propyl~isobenzofur~n were dissolved in 9. 8 parts 5 of a hydrochloric acid solution 0. lM and 788 parts of etha~ol and the whole wa.s stirred and refluxed for one hour. The solve:Qt was e~raporated and the re~idue was taken up in methylben~ene and water. The organic pha~e was separate, washed with wa~er, dried, filtered a~d e~aporate~L The residue was purified by column-10 chromatography o~ter silica gel u~ing a mixtu~e trichloromethaneand metha~ol (~9:1 by ~rolurne) as eluent. The pure fraction3 were collected and the eluen~ wa~ e~raporated, yielding Z4. 2 part~ of 1 ~(4-fluorophe~yl)-1, 3-dihydroisobenzofuran-l -pr opanol as a re~idue (i~termediate 11).
To a s~irred ~olutio3~ of 24. 2 par~s of 1 -(4-fluorophenyl)-1, 3 dihydroisobenzofuran-l-propanol ill 8 parts of pyrid~ne and 90 parts of tTichlorome~harle were added dTopwi e 12.1 parts of thionyl chloride. Upon completion, the whole was heated slowly to 50C
and stirring at this temperature was continued for 3 hours. The 20 reaotion mixture wa~ poured orLto ice-water. The organic phase was separated, washed with a sodium hydrogen carbon?te solution (10%), dried a~d evaporated, yielding 20 part3 of 1-(3-chloropropyl~
(4-fluorophenyl)-1, 3-dihyd~oisober~zofuran as a residue (ir~termediate 12) Z5 ~!~
70 Part~ of 4-fluorobe~zeneacetonitrile were heated at 120C ~nd these were added dropwise 83 parts of bromi~e and stirring was conti~Lued for 30 mi~ e~. The resulting reaction mixture wa~ a.dded dropwise to ~-slirred mixture (roos~ temperature) of 85 parts of 30 alw~ninium chloride and 200 parts of fluorobenzene (exothermic reaction: temperature ri~es to 50C) After stirring for 30 minutes at 50C, the reaction mixture was po~red onto a m~xture o~ crushed ice and 7~ parts o~ hydrochloric acid solutio~L The product was extracted with methylbenzene The extract was dried and e~raporated.

3~23L~3~3~

The residue was cryqtallized twice from Z-propa~ol, yielding 51 part~ of 4-fluoro-a-(4-fluorophe~yl)ben~eneacetonitrile, mp.
63. 5 C (i~termediate 13) To a sl:irred a~d cooled (i~e-~ath) mixture of Z2 9 parts of 4~fluoro-a-(4-fluorophenyl)be~ eneacetonitrile, 23 6 part~ of 1 bromo-3-chloropropane and 0. 4 part3 o~ N,N,N-triethylbenze~e-methanarninium chloride were added dropwi~e 600 parts of qodium hydroxide solutio~ 50% at a temperature below 30C. Upou completio~, stirr~ng was co~tinued for 3 hour~ at 50-60C.
Methylbe~zene and water were added ~d the layers were separated.
The orgaIlic phaqe was dried, filtered arLd evaporated. T~e re~idue was evaporated once more in ~acuo for 30 minutes at 100C to remove the last trace~ of l-bromo-3-chloropropane, yieldirLg 29 parts (95%) of Q-(3-chloropropyl)-4 fluoro~a-~4-fluorsphenyl be~zeneacetonit~ile as a residue (intermediate 14) A mixture of 3 parts of a-(3-chloropropyl) 4-fluoro~Q-(4-fluorophenyl)benzeneacetonitrile, 92 parts of co~cerltrated sulfuric acid, 50 parts of water a~d 50 par~s o~ acetic acidwas stirred and refluxed for 24 hour~ The reaction mixture was conce~trated to about 100 parts and the product wa3 e~racted with methylbenzene.
The extract was wa. hed with water, dried, filtered a~d e~aporated.
The residue was sugpea~ded in petroleumether. The product was filtered off and crystallized from 2, 2'-oxybispropane, yieldin~
1. 41 parts of 3, 3-bis(4-fluorophenyl)tet~ahydro-ZH-pyra~-Z-oIle;
mp. 122. 4C (iIltermediate 15~.
~ mixture of 5. 8 parts of 3, 3~bis(4-fluoropheuyl)tetrahydro-2H-pyra~-2 one aIld 30 part~ of a solution of hydrobromic acid in glacial acetic acid was stir~ed over week-end at room temperature.
Th0 reactiorL mixture wa~ polLred onto water The precipitated product wa~ filtered off a~d dissolved i~ 2, 2'-oxybispropane. The organic pha3e wa~ washed with watex, d~ied, filtered and Pvaporate~
The re3idue was boiled in a mixture of 42 parts of 2, 2' -oxybis-proparle and 42 part~ of petroleumether. The produot wa~ filtered off a~d crystallized from 2, 2'-oxybi~propane, yieldi~g 1 Z7 parts V3~

of a-(3-bromopropyl)-4-fluoro-a-(4 fluoropheuyl)be~zeneaceSic acid~ mp. 161 C (intermediate 16).
To a stirred solution of 29. 5 part3 of a-(3-bromopropyl)_4-fluoro-a (4-~luorophenyl)benzeneacetic acid in 300 part3 of trichloro-metha~:Le were added Z8. 8 parts of thionyl chloride and the whole was stirred and refluxed for 3 hour~ The reactioll mixture was e~raporated, yield~ g 30 part~ of a-(3-bromopropyl)-4-fluoro-a-(4 fluorophenyl)benze~eacetyl chloride as a residue (intermediate 17).
A mixture of 30 pa~ts of a - (3 -br omopr opyl) -4-fluor o - ~ -(4 -fluorophenyl)benzeneacetyl chloride, 9. 3 part3 of e~hanol a~d 90 parts of methylbe~ene was ~tir:red o~er2ight at room tem-peratu~e. The reaction mi~xture was evapora~ed, the residue wa~
take~ up i~ etha~ol and the latter wa~ e~raporated agai~.
The residue wa take2l up iu 2, 2'-oxybiipropane. The whole was washed with a satu~ate sodium hydrogen carbonate solution and with water, dried, filtered and e~raporated. The residue was purified by column-chromatography over 9ilica gel using a mixture of trichloromethane and hexarLe (50:50 by ~rolume) aq eluent. The pure fraction~ were collected and the eluent was e-~aporated, yielding 19. 6 parts of ethyl a -(3-bromopropyl)-4-fluoro- Q -(4-fluorophenyl)-benzeneacetate as a re~idue (i~termediate 18).
Example :~
To a stirTed and cooled (ice-bath) mixture of 50 parts of fluoro-benzene arLd 4. 1 part~ o~ 4-(4-fluorophe:~yl)-4-hydroxycyclohexanone were added portiollwi~e 11 part~ of alumirliurn chloride, Upon completion, stirring was co~tinued for 2 ho~ while ~till cooling.
The reactio~ mixture wa~ decomposed by pouri~g o~to a mixture of crushed ice a~d a hydrochloric acid qolution The product was e~ractecl with methylbenzene. The extract wa~ wa~hed with water till neutralizatio~, dried, filtered and evaporated. The re~idue was puri~ied by column-chromatography over silica gel using trichloro-methane as eluent. The pure fraction~ were collected and the eluent wa~ e~raporated, yieldi~g 4. 3 parts (75. 9~) of 4,4-bis(4-fluorophenyl)-l_cyclohexanone a~ a residue (i:ntermedia~e 19).

E~
A mixture of 10 parts of bis(fluorophe~yl)me~hanone, 22. 1 parts of 3-chloro-1, 2-propanediol9 0 2 part~ of 4-methylbenzenesulfonic acid hydrate, and 90 parts of methylbenze~e was s~irred a~d refl~Lced for 23 hours u~i~g a water-separator The reaction mL~tu2e was poured onto aL~cali~Le water Upon stirring, the layer~ were -~eparated The organic pha3e wa~ washed with alkaline water, dried, filtered a~d e~raporated, yield~g 14 parts (100%) of 2, Z-bis(4-fluorophe~yl)-4~(chloromethyl)-l, 3-dioxola~e as a re~idue 1 0 ( in~ermediate 2 0 ) .
~I
To a 3tirred suspension of 112 parts of 2, 3-dibrosnobutanamide in 880 parts of acetonitrile were added 91 part3 of N,N-diethyl-ethanamu?e a~d the whole was stirred for 4 hours at room tem~
perat~:re. The formed precipitate was filtered off. To the filtTate were added 112 parts of N,N'-bis(phenylmethyl)_1,2-etha~ediami~e a~d 45. 5 parts of N,N-diethylethanamine and stirri~g was continued for Z. 50 hour~ at room tempera~ure. The whole wa~, fur~her stirred for 36 hour~ at reflux tempera~ure. The reaction mixture was cooled a~d filtered. The filtrate wa~ evaporated in vaeuo. The residue was heated in 675 parts of methylbenze~e. The mixture was filtered and the filtrate was evaporated. The oily residue was purified by colum~-chromatography ove2 silica gel using a mix~ure of trichloro-methane a~d methaDol (95:5 by volume) as eluent. The pure fractiorls were collected and the eluent was evaporated. The residue was cry~tallized ~rom 2-propa~ol, yielding ll part~ of 1, 4--bis(phenyl-methyl)-2-piperazineacetamide; mp. 113. 8G (i~termediate 21).
Exanl~le XII
A mixture of 55. 2 parts of methyl 2-pyrazinecarboxylate, 48. 9 parts of 2-aminoethanol and 360 part3 of ethyl acetate was allowed to stand o~ ernight at room temperature. The precipitated produet wa~ filtered of, washed with ethyl acetate and dried, yielding 54. 5 parts (80%) of N-(2-hydroxyethyl)-2-pyrazinPcarbox-amide; mp. 125C (intermediate 22).

~6 Exarsl~le XIII
A mixt~re of 53, 7 part~ of N-(2-hydroxyethyl)-Z-pyrazine-carboxamide, 20 part~ o calciurn oxide and 500 parts of 2-methoxyethanol wa~ hydrogenated at normal pressure and at room temperature with 5 part of palladium-oll~charcoal catalyst 10%, A~ter the calculated amount of hydrogen wa~ ta}ce~ up, the catalyst was filtered off and the filtrate wa~
e~aporated, yieldi~g 55. 4 parts (100%) of N-(2-hydraxyethyl)-Z-pipe~azi~ecarbo:~amide as a residue (intermediate 23~, Followi~g the same hydrogenatio3l procedure there were also prepared:
N,N-dars~ethyl-Z-piperazinecaxboxamide as an cdly residue (intermediate 24);
N-methyl-2-piperazirlecarboxamide as a residue (irLtermediate 25~;
N-(l-methylethyl)-2-piperazi~ecarboxamide a~ a residue (intermediate 26); and trans-3-methyl-Z -piperazi~ecarboxamide; mp. 165 ~C
(i~termediate 27).
Examl~le XIV
To a stirred mixture of 60. 5 parts of a-methyl-l, 4-bis(phenyl-methyl)-2-piperazinemetha~ol a~d 180 par~ of N, N dimethylform-amide were added portionwise 29. 8 part~ of a sodium hydride dis-persion 50% at a temperature below 35C; ~der nitrogeD. atmosphere.
The mixture was allowed to cool and stirred for 3 hours at room 2~ temperatUTe. After cool~ng to 10C, there were added dropwise 9. 4 parts of iodomethane at about 20C. Uporl completion, stirring wa~ co~ti~ued for 2 hours at room temperature. The reaction mlxture was poured onto water and the product was extrac~ed twice with 1, 1 ' oxybisethane. The combined extractq were washed with water, dried, filtered and e~raporated, yieLding 45. 2 parts (71. 5q~) of 2~ methoxy_ ethyl)-174-bis(pherLylmethyl)pipera2ine as a residue (i~termediate 28).

~2~

Follsw~g the aame procedure, and using iodomethane, respectively, bromoethane a3 an allcylating age~t, l:here were also prepared:
2-(methoxymethyl)~ -bis(phenylmethyl)piperazlne aq a r e qidue (iD.termediate 2 9); and 2-(ethoxymethyl)-1,4-bis(phe:~ylmethyl)piperazi:~e as a residue (~ter~nediate 30).
E~XV
A mixture of 117 parts of 2-(methoxymethyl)-l, 4-bi3(phenyl-methyl)piperazine and 400 parts of me~ Lol wa~ hydrogenated at normal pressu~e and at room temperature with 5 parts of palladium-o~-charcoal ca alyst 10% After ~e cal~-ulated amou~t of hydrogen was taken up, the ca~alyst wa~. filtered oi~ and the filtrate was evaporated. The resi~ue wa~ di~tilled, yieldi~g 38. 6 part~ (78. 8%~ o 2-(methoxymethyl~piperazine; bp. 75-80C
(i~termediate 31).
Followin2 ~he same hydrogerLation procedure there were al~o prepared:
2-(ethoxymethyl)pipera2ine as a re~idue (intermediate 323;
2û a-methyl-2-piperazi~emethaYIol (intermediate 33);
2-piperazirLeacetamide; rnp. 152C (intern~ediate 34), and 2-(1 methoxyethyl)piperazine as a residue (intermediate 35).
Example XVI
To 1 part o a iolution of 2 part~ o thiophene i~ 40 part~ of etha~oL were added 2. 2 parts of be~zaldehyde, 2. 6 parts o 2-piperazinecarboxamide and 120 part~ of methanoL The whole was hydroge~:Lated at ~ormal pre~sure and at room ~emperature with 2 parts of plat~um-on-charcoal cataly3t 5 %. After the calculated amou~t of h~drogen wa~ take~ up, the catalyst was filtered of a~d the filtrate wa~ evaporated. The solid residue was boiled ~ 64 parts of acetonitrile The mixture was filtered and the filtrate was allowed to crystallize at room temperature. The product wa~ filtered off and dried, yieldiIlg 2. 4 parts (55 %) of 4-(phe~ylmethyl)-2 _ piperazi~ecarboxamide; mp 168. 3C (intermediate 36).

lV;~''3~i;

:E~ollowing the sa~ne reducti~e amination procedure there were also prepared:
4-(pherlylmethyl)-2-piperazinemethanol (~ 2-butenedioate (1:2); mp 189 8C (intermediate 37);
3-(methoxymethyl)-1-(phenylmethyl~piperazine as a residue termediate 38);
N9 N -dimethyl-4-(phenylrnethyl) -2 -piperazinecarboxamide a~ a residue (i~termediate 39~;
3-~ethoxymethyl)~ phenylmethyl)piperazine aR a residue (i~termediate 40);
a methyl-4-(pherLylmethyl)-Z-piperazinemetha~ol; mp. 100. 3C
(intermediate 41);
4-(phe~ylsslethyl)-2-piperaz~eacetamide; mp. 110 1 ~C
(in~ermediate 42);
(A).3~ methoxyethyl)-1 (phenylmethyl)piperazi~e as a re~idue (intermediate 43);
(B) 3-(1-methoxyethyl)-1-(phenylmethyl)piperaz~:Le as a reidue (i~termediate 44); and ethyl 4-~phenylmethyl)-2-piperazineoar~o~ylate as a residue (intermediate 45).

A mixture of 13. 2 parts of 4~(phenylmethyl)-2-piperazine-carboxamide, 18. 5 part~ of 1,1 '-(4-chlorobutylidene)bis~-fluoro-be~ze~l~7, 14. 8 parts of 30dium carbo~ate, 0. 1 parts o potassium iodide and 200 part9 of 4-methyl-2-pe~ta~one w~s stirred a~d rsfluxed for 7Z hourY U9i~g a water-separ~to~ The reaction mixt~e was cooled to roonl tempsrature, filte~ed a21d the filt~ate was evaporated.
The oil~r residue ~a5 purified by colum~chromatograp}~y over ~ilica gel U~iIlg a m~ture of trichloromethane and methanol (97:3 by volume) as eluent~ The pure fraction~ were collected and the eluent waR e~raporated. The re4idue was cry~tallized frorn 2, 2' oxybis-propane The product wa~ filtered off and dried, yielding 17. 7 parts (63. 6 %) of 1 -C4~ 4-bi~(4-fluorophenyl)buty~7 -4 -(phenyLrnethyl) -2 -pi~erazi~ecarboxacnide; mp. 79. 2~C (i~termediate 46).

U~5 Following the same N alkylation procedure there were also prepared:
1 ~4, ~-bis(4-fluorophenyl)buty~7-4(phenylmethyl)-2-piperazine-methanol ethanedioate (1:2); mp. 158 4C (intermediate 47);
ethyl 4-~diphenylmet}~ 2-piperazineca:rboxylate; mp 95, 1 C
(inter~nediate 48);
4-~3-phenyl-2-propenyl) 2-piperazinecarboxamide; mp, 1~9. 6C
(intermediate 49);
l -~4, ~-bis(4-fluorophenyl)buty~7-N, N-dimethyl-4~(phenyl-10 met~yl~-2-piperaz7necarboxamide as a residue (intermediate 50);
1 -r4, 4-bis(4-flllorop~e~Lyl)buty~7-2 -(methoxymethyl) -4-(phenyLmethyl~piperazine as a re~idue (intermediate 51); and ethyl 1_~4, 4-bis(4-fluorophe~yl)buty~7-4-(phenyLmethyl) 2 -piperaz~necarboxylate a~ a residue (intermediate 52).
~L~
A mixture of 14. 8 part3 of 1-~4, 4-bis(4-fluorophenyl)buty~7-4-(phenylmethyl)~2-piperazinecarbox2mide and 200 part~ of metha~ol wa~ hydrogenated at normal pressure aad at room temperature with 2 part of palladium-on-charcoal catalyst 10%. A~ter the calculated amoullt o hydrogen wa~ ta~ce~ up, the catalyst was filtered off a~d the filtrate was e~raporat~d. The r~-~idue was purified by eolum~-chroma-tography over silioa gel using a mixture of trichloromethane and methanol (85:15 by volume) as elues.t. The pure f~actions were eollected and the elueslt waq evaporated. The residue was crystallized rom 2, 2'-oxybispropane, yield~g 7. 9 parts (66. 4%) of l -~4, 4-bis(4-fl1~orophenyl)buty~7-Z-piperazillecarboxamide; mp. 113. 6C
(intermediate 53).
FollowiD.g the ~ame hydrogenation procedure a~d startlng from the corresponding phenylmethyl derivative3 there were al~o prepared:
3~ 4, 4-bis(4-fllaorophenyl)buty~7~2 piperazineme~ha~ol (intermediate 54);
4, 4-bis(4-fluorophenyl)buty~7-N, N-di~nethyl-2-pipera~ine -carboæamide as ar~ oily residue (intermediate 55);
4, 4-bis(4-fluorophenyl)but~ 2-(methoxymethyl)piperazine as a residue (i~termediate 56); and 3~5 ethyl 1-~, 4-bi~(4-fluorophenyl)buty17-2-piperazinç~ arb~ylate as a re~idue (intermediate 57).
E:xample XIX
To a stirred and cooled (10C) 901UtiO~1 of 7. 8 part~ of 3-5 (meth~cymethyl)-l_~phenylmethyl)piperazine in 150 parts of trichloro-metha~e were added dropwi~e during a lO m~nutes~period 8. 4 parts of t:rifluoroacetic acid anhydride: exothermic reaction, the temperature ri e~ to 25C (cooling with ice-water). Upozl completion, stirr~g wa~ conl:i~ued for 3 hours at rc~o~n temperature. The reactio~ mixtuse 10 was eYaporated. The re~idue wa~ puriied by colum2:L-chromatography over silica gel u~g a m~re of trichlorometha~e and methanoL9 saturated with ammonia, (95:5 by volume) a~ eluent. The first fracti~ were collected a~d the eluent wa~ evapora~ed, yielding 9, 2 part~ (83%) of Z-(methoxymeth~ 4-(phenylmethyl) 1-15 (tri~luoroacetyl)piperazine a~ a residue (~termediate 58).
A mixture of 9. 2 parts of 2-(methoæymethyl)-4-(phe~ylmethyl)-l-(trif~uoroa~etyl)pipera~ine and 120 parts of methanol was hydro-genated at normal pressure and at room temperature with 2 part~
of palladiurn-on-charcoal cataly3t 10~. After the calculated amount 20 of hydrogen wa~ taken up, the ca~aly3t wa3 filtered off and the filtrate wa~ evaporated, yielding 6. 05 parts (92 %) of 2-(methoxymethyl~
(trifluoroacetyl)pip~razi~e as a re~idue (iIItermediate 59).
To a stirred mixture of 6. 05 parts of Z-(methaQcymethyl)-l-(tri-fluoroacetyl)piperazine, 5, 25 parts of N,N-diethylethanami~:Le ant 2S 36 parts of N,N-dimethylformamide were added 11 parts of 1,1'-(4..iodobutylide~e)biqC4-fluorobenzene7. Stirri~g waq conti~ued for 4 hour~ at 75C. The reac~io~ mixture wa~ eooled and poured o~to 400 part~ of water. The product was extracted twice with 140 parts of l,ll-oxybi~etharLe, The combined extract~ were dried, filtered and evaporated7 yieldi~g 11, 5 part3 (94~) of 4-~4,4-bis(4 fluoro-pher~yl)buty~7 -2 -(methoxymethyl) -1 -(tri~luoroacetyl)piperazi:~e as a residue (intermediate 60).
A mixture of 11, 5 parts o 4-/4,4-bi~(4-fluorophenyl)buty~7-2-(methoxymethyl)-l-~trifluoroacetyl)piperazine and 60 parts of hydrochloric acid 301ution 6N were stirred a~d refluxed ovemight.
36 The reactioll mixture was cooled and washed with 70 parts of 3~

1,1 '-oxybisethane. The acidic aqueou~ phase was aL'calized with am-monium hydroxide, The product was extracted twice with 70 part3 of 1, l ' -o.~ybisethane, The combined extracts were dried, filtered and evaporated, yielding 6, 7 parts (72%) of 1-~, 4-bis(4 fluorophenyl)-S butyi7-2-(methoxyrnethyl)piperazine as a residue (intermediate 61).
Example XX
To a stirred a~d cooled (abou~ 10C) solutiorl o 11. 7 part~ of 2 methoxy-5-(trifluoromethyl)benzerlami~e in 50 parts of acetic acid were added dropwise 7, 7 parts of chloroacetyl chloride at a ~empera-ture below 20C;, After 3tirring for 30 minutes, ther~ was addecl dropwi~e a solution of 24, 8 parts of sodiurn acetate in 62 parts of water (exothermic reaction), Upo~ completion, qtirring was continuet for 30 minute~ at room temperature. The precipitated product was filtered off, washed with a lot of water and dried, yielding 15. 5 pa:~ts (93, 3%) of 2-chloro-N-~-methoxy-5 (trifluorornethyl)phe~yl7-acetamide; mp, 94, 7C (intermediate 62), In a si~nilar manner there were al30 prepared:
3-chloro-N-(2, 6-dic~lorophenyl)propanamide; mp. 1~3C
~intermediate 63);
2-chloro ~N-(5-fluoro-2 ~methylphenyl)acetamide; mp. llO. 1 C
(intermediate 64); and 2-chloro-N-(5-chloro-2-methylphenyl)aceta~nide; mp. 138. S C
(intermediate 6~ ~.
E~
To a ~tirred solution of 49. 2 parts of 2-methoxy-~-methyl-ben~enami~e and 270 parts o~ methylben~ene were added dropwise 22. 5 parts of 2-chloroacetyl chloride while cooling (ice-bath) at 10-20C, Upon cornpletio:n, stirring waR continued for 1. 50 hours at room ternperature, 205 Farts ~ water were added, The orgarlic pha~e was ~eparated, washed with water, dried, filtered and eva-porated, The oily re~idue was crystallized from 2, 2'-oxybispropane, ~he procluct was filtered of and dried, yielding 2~, 2 parts (66%) of 2-chloro -(2-methoxy-5-methylphenyl)acetamide; mp, 83, 9~C
(intermediate 66), Ir~ a similar manner there were also prepared:

2-chloro-N-(2, 6-dichloro-4-cya~ophenyl)acetamide (inter-mediate 67);
N-(4-acetyl -2, 6 -dichlor ophenyl) -2 -chlor oacetamide (inter -mediate 68); and 2-chloro~-(5~chloro-2-methoxy-4-nitrophenyl)acetamide;
mp. 130. 9C (inter~nediate 69) Example XXII
To 1 part of a solution of 2 parts of thiophene i~ 40 parts of ethanol were added 15 parts of 2-chl~ro;N-(2-methyl-4~nitropherLyl)~
10 acetamide a~d 400 part of metha~ol. The whole waR hydrogerlated at ns:~rrrlal pres~ure and a~ room temperature with 2 parts of platinum-on-charcoal catalyst 5 %. A~ter the calculated amo7-nt of hydroge~ was take~ up, the catalyst was filtered off and the filtrate was evaporated.
The solid residue was purified by colurn%~-chromatograp~y o~rer 15 ~ilica gel U8~1g a mixture o trichloromet~Lne and methanol (95:~ by ~olusne) as eluent. The pure fractio~s were collected and the eluent was evaporated. The reaidue was 3u3pended in 2, 2'-oxybispropane. The product was filtered off arLd dried, yielding 12 parts (92%) of N-(4-3mino-2-methylphenyl)-2-chloroa~etamide 20 (intermediate 70).

36. 8 Parts of co~ce~trated ~ulfuric acid were stir~ed and cooled to 0C a~d there were added portionwi~e 4. 2 par,s of 2-chloro-N-(2, 6-dichloro-4-cyanophe~yl)acetamide. Upon completion, stirring 25 was continued for 3 hour~ in an ice-bath The reaction mixtuse wa3 allowed to stand overnigth at room temperature and poured onto ice-water. The precipitated product was filtered of~, wa~hed wi~h ~ater, dried and boiled in aceto~itrile. The product wa3 filtered o~f and dried, yielding 2 7 parts of 3, 5-dichloro-4-~2-chloroacetyl)-30 amillo7be~za~ide; mp. *260C (~Iltermediate 71).Example XXIV
A mixture of 12 8 part~ of N -(2, 6-dimethylphenyl)-~-(phenyl-methyl)-l, 2-piperazinediacetamide and 120 parts of methanoL was hydrogenated at normal pres jure a~d at room temperature with 35 2 parts of palladium-on-charcoal catalyst lO(lo. After the calculated 3~5 amou~t of hydroge~ was take~ up, the catalyst was filtered oi~ ~d the filtrate was eYaporated. The oily residue was crystallized f~om acetonitrile, yieldiIlg 7, 7 parts (97 5%) of N -(2, 6-dimethylphenyl)-1,2-piperazi~ediacetamide; mp. 171, 9~C; (i~termediate 72), Following the sa~ne hydrogenatio~ procedure a~d sta~t~g from the correspo~di~g phe~ylmethyl derivatives there were al30 prepared:
N-(2, 6-dimethylpher~yl)-Z-(hydroxymethyl)-l -piperazine-acetamide; mp 134. 1C (i~termediate 73);
2-(ami~ocarbo~yl)-N-(2, ~-dimethylphenyl)-l-piperaZiDe-acetamide as a ~olid residue (intermediate 74);
ethyl 1-~ Z, 6-dimethylphenyl)asnin~7-2oxoethy~ Z-piperaæinecarboxylate as a residue (intermediate 75);
N-(2, 6-dimethylphenyl)-2-(metho~ymethyl)-1 -piperaz~e-aceta~nide as a re~idue (i~termediate 76);
2-(dimethyLamiYlocarbonyl)_N_(2, 6-dirnethylphe~yl)~l-piperazineaceta~ide as a residue (i~termediate 77);
(A+B) =N-(29 6-dimethylpheDyl)-2-(ethoxymethyl)-a-methyl-l-piperazineacetamide a~ a re~idue (intermediate 78);
2 a N-(2, 6-dlsnethylphenyl)-2-(eth~xymethyl)-1 -piperazir~ea~et-an~ide as a re~idue (intermediate 19);
N-~2, 6-dimethyLphsnyl)-2-(1 -hyd~oxyethyl)-l -pipera~ine~
acetamide; mp. 151. 9~G (intermediate 80);
(B)-N-(2, 6-dimethylphenyl)-2-(1 -sneth~cyethyl)-l-piper-aziueacetamide as a residue (IntPrmediate 81); a~d (A)-N-(2, 6-dirnethylphenyl)-2-(1 -methoxyethyl)-l-piperazine-acetamide as a residue (~termediate 82).

To a stirred and warm ~olutiorl of 3 part3 of 2-piperazine-carboxamide in 16 parts of 2-methoxyethanol were added 51 2 parts of 2-propanone. The whole was stirred a~d refluaced for 20 hours.
The reaction mixture was e~raporated. The ~olid residue wa~ crystal-lized from acetonitrile, yielding 2. ~ partq (64%) of he~ahydro- 3, 3 dimethylimidazo~, 5-a7pyraz~-1 (5H)-one; mp. 174. 2C
(i~termediate 83).

In a simi1ar mamleI there were also prep~Lred:
hexahydro-2, 3, 3-trimethylimidazo~, 5-a~pyrazin-1 (5Hj-o~e as a residue (intermediate &4);
hexahydr o-2 -(2 ^hydroxyethyl) ~3, 3 -dimethylimidazo~, 5 pyrazin~ H)-o~e; mp, 95C (intermediate 85);
hexahydr o-3, 3 dimethyl -2 -(1 -methylethyl)imidazo~l, 5 pyrazin-1(5H)-one (intermediate 86);
hexahydro-3, 3, 8-trimethylimidazoL~, 5-aJpyrazin-1 (2~)-one (~termediate 87); arLd N-(2, 6-dichlorophenyl)hexahydro-3 methyl-(2~methylpropyl)-1 -o~coi~nidazoL~, 5 -~7pyra:zine -7(8H)-acetamide; mp. 227. 3 C
(intermediate 88).
Example XXVI
To a ~tirred solution of 45 part~ of 2-piperazinemethanol in 211 parts of warm 2~methoxyeth~ol were added 675 part~ of 2-propanone and stirring wa~ conti~Lued for 27 hours at reflux temperature. The reaction mixtu:re was allowed to cool to room temperature over week-end. The solvent was evaporated and the residue was takell up irL methylbenzene. The mixture was filtered yielding 41 4 part of hexahydro-3, 3-dimethyl-3H-oxazolo~, 4 pyrazlne.(i~termediate 89).

A mixt~lre of 169. 8 parts of 1, 1 '-~4-chlorobutylidene)bisL4-fluorobenze~e~7, 93. ~ parts of hexahydro~3, 3-dimethylimidaæo/1, 5-aJpyrazin-1~5~ one, 128. 3 part~ of sodium carbonate, 0. 1 parts of pOta95illm iodide ar~d 1200 parts of 4-rnethyl-2-per.tanone was ~tirred and reflu~ced for 8 hours using a water ~separator. After cooli~g overnight to room temperature, the reaction miYture was filtered.
The filtrate was evaporated. The re~idue was purified by columll-chromatography o~er silica gel using a ~nixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent ~ras evaporated. The residue was triturated i~ 2,Z'-oxybispropane. The product was filtered off and dried, yielding 108 parts of 7-~4,4-bis(4-fluorophenyl)buty~7hexahydro-3,3-dimethylimidazo~,5-~7pyrazi~-1(5H)-oue; mp. 148. 4C (inter-3~ mediate 90).

~2 Following the same N-a~lcylation procedure, and u~ing equi-vale~t arrlou~ts of the apps opriate starting materials, there were also prepared:
7-~4, 4-bis(4-fluorophenyl)butyl7hexahydro-Z, 3, 3-trimethyl-imidazo~,5-a7py~raz~-1(5H~_orle monohydrochloride (intermediate 91 );
7 ~[4, 4 ^bis(4-fluor ophenyl)buty~7hexahydr o-2 -(2 -hydr oxy~
ethyl)-3,3-dimethylimidazo/ ,5-a7pyrazin-1(5~)-one as a residue (iIltermediate 92); a~d 7-L-49 4-biq(4-fluorophenyl)buty~7hexahydro 3, 3-dimethyl-2-~l-methylethyl)imidazo~,5-a;7pyrazirL-1(5H)-on~ as a residue (ix~termediate ~3).
Example XXVIII
A m~ e o 30. 7 parts of 1,1 '-(4-iodobutylidene)bis~4-1~ fluorobenzene7, 11.5 parts of hexahydro-3,3-dimethyl-1~.-oxa~olo-~, 4-a7pyrazine, 1~. 8 part-~ o sodium carbonate arld 270 parts of N9N-dirnethyl~orrnamid~ was stirred for 5 hours at about 70C.
The reaction mixture was cooled o~ernigh$ to room temperature a~d the ~olvent was evaporated The residue was dissol~red i~
trichlorornethane. The organic phase was wa3hed with water, dried9 filtered and e~aporated9 yieldirLg 34 parts, of 7-~4, 4-bii(4-fluoro-phenyL)buty~7hexahydr o-3, 3 ~dimethyl-l H -oxazoloL~, 4-a7pyra7i~e a~ a residue (i;Rtermediate 94).
Example XX~
A mixture of 40 parts of 7-~4,4-bis(4-fluorophe~yl)buty~7-hexahydr o-2 -(2 hyd2 oxyethyl) -3, 3 -dimethylimida20~, 5 -a~pyra2~-1(5H)-one, 19 parts of hydrochloric acid solution 10. 5N a~d 400 parts of water was stirred for one hour i~ a boiling water-bath o~ a Rotavapor. After cooli~g, the reaction mixture wa3 washed twice with 140 part3 of 1,1'-oxybisethane The a~ueous phase wa~ alka lized with ammonium hydroxide. The pxoduct was extracted twice with 140 parts of l,l'-oxybisetha~e The combined extracts were dried, filtered and evaporated. The re~idue wa~ purified by column-chromatography over silica gel u~ing first a mixture of trichloro-methane and rnethanol (90:10 by volume) a~d then a mixture of trichloromethane and methalLol saturated with ammo~ia (90:10 by volume) as eluen~s. The pure fractionq were collected and the elue~ was evaporated, yielding 33, 7 parts (100%) f 4-L4,4 -bis(4-fluorophe~yl)buty~7-N-(2-hydroxyethyl)-2-piperazi~ecarboxamide (intermediate 95).
~ a similar ma~èr there were al~o prepared:
4-~9 4 bis(4-fluorophenyl)buty~7-N-methyl 2 -piperazine-carboxarnide as a residue (Lrltermediate 96);
4-~, 4-bis(4-fluorophenyl)butyi7-2-piperaz~ecarboxamide as a~ oily re~idue (illtermediate 97);
4 ~4, 4-bis(4-fluorop}lenyl)buty~7-N~ methylethyl)-2-piperazinecarbo~amide (intsrmediate 98); and trans -3 -(aminocarbanyl) -N -(2, 6 -dichlor ophe~yl) -~ -methyl -l-piperazineacetamide; mp. 254. 6C (intermediate 99).
Exam~7le XXX
_ .
A mixture of 34 parts of 7-L~, 4-bis(4-fluorophenyl)buty~7-hexahydr o-3, 3 -dimethyl 1 H -oxazoloL3, 4-a7pyrazi~e and 272 parts of a hydrochloric acid solution 0. 5 N in water was stirred a~d refluxPd for 2 hours. The reaction mixtu~e was cooled to room temperature a~d the product was extracted twice with 1,1 I-GXy bi~ethane. The aqueous pha~e was separated, alkalized and 3alted ou~ with sodium carbonate. The product was ex~acted with trichloro-~netha~e. The e~ract was dried, filtered and evaporated. The residue was purified by colurnn-chromatography over silica gel using a mixt~;re of trichloromethan2 and me~ha~ol (85:15 by volurne~, sat~rated with ammonia a~ elue~t. The pure fractions were collected a~d the elue~t was evaporated, yieldina 17. 0 parts o 4~4, 4~,bis~4-fluorophenyl)buty~7 -2 -piperazinemethanol as ar~
oily re~idue (intermediate lO0) Example XX~I
A mixt~e of 8 2 part3 of 2-chloro-N-(2, 6-dimethylphenyl)-acetamide, 7 2 part~ of hexahydro-3, 3 dimethyl-2 -(l -methylethyl)-imidazoL~,5-a7p~razin-l(5H)-one, 7 part9 of N,N-diethylethanamLrle a2~d 54 part~ of N,N-dimethyl~ormamide was qtirred and heated for 3~

3 hours at 7St:;. After cool~g to 0C, the precipitate wa3 filte~ed off and the filtrate was evapo~ated. The residue wa~ di~sol-red in 300 parts of trichloromethane. Thi3 ~olution was washed with 50 parts of water, dried, filtered and evaporated. The residue was 5 triturated in 2, 2'-oxybi~propane After coolîng to 0C;, the product wa~ filtered o~ a~d dried, yieldi~g 9. 2 partq (72 7 %) of N-(2, 6-dimethylphenyl)hexahydro 3, 3-dimel:hyl-2~ methyl-ethyl)-l -oxoimidazo~, 5-~7pyrazine-7(8H) -acetamide; mp. 1;5 C
(i~termediate l Ol ).
F~llowing the same N-alkylatiorl procedu:re, and usi~g equi-~alent amou~lt~ of the appropriate starti~g rnaterials, there were al~o prepared-~
~1 -N ~ N CH2 -(; -NH-aryl H3C ¦

. _ ter~ ri r2 aryl mp. C
' ~ , ~ - . . .
102 iCH3 H 2. 6-(CH3)2 C6H3 180 103 IH H Z 6-(CH3)Z C6H3 194. 8 104 ¦C~(CH3)Z 1 ~ ~ 2 C6H3 105 ICH2-CHZO~ ~ 2 6 3 106 CH3 H 2 6-C1? C6~3~ 17 .. 6 107 C~3 H 2 -C1. 6 C~3 ~ 6 3 17~. 1 1 0 8 H H 2 4, 6 - (~ H3 ) 3 -~ 6HZ
109 H I H 2-CH3 6-C2H5-C 6H3 160 . 4 110 ;H I H 2 6-~H(~H3)~2 C 6H3 oil 111 ¦~H3 I 2 COGH3 C6 ~ 1~9. 0 112 IC~3 H 2 4 6-(CH3)3-~6~2 117.6 113 !H H 2 GO~C~3 C6 4 207. 6 1 1 4 I C H3 H 2 6 - (C H3 )2 4 N~ )2 C 6~2 1 91 . 9 115 H H 2 6 C12 C6H3 207. 9 116 C~3 H 2 CH3 4_NO2~C6H3 201. 6 I L ~ C~l; 11 2-CH3, 5-Cl-C61~3 ~ 199. 7 ! Irlter -media~ ! rr r2 aryl mp. C
. . ___ . . __ ~
119 H CH3 2~ 6 C12 C6H3 120 H H 2-OCH3-C6H~- 189, 8 Exam~le XXXII
A mi~ture of 6. 6 par~ of 2-chloro-N-(5-fluoro 2-methyl-phenyl~acetamide, 5 parts of hexahydro-3, 3~dimethyl-3H-oxazolo~
~,4-a7pyra:~ine, 6.1 parts of N,N-diethylethanamirLe a~d 67. 5 par~s of N, N-dimethylformamide was sti~red and heated for 8 hours a~
about 70C. A~ter cooling overIlight to room temperature, the reactio~ mixture was evaporated. The residue was diqsolved in trichlc)rometha~e. The solution wa~ washed with water, dried, filtered a~d e~raporated, yielding 8. 5 parts of N-~5-fluoro-2-methyl-phenyl)-tetrahydro-3, 3-dimethyl-3H-aæazolo,~, 4-a7pyrazinF~-7(8~ acetamide a~ oily residue (interrnediate 121) Followi~lg the same N-alkylation procedure and u~ing eaui-valent a~ounts of the appropriate starting materials there were al30 prepared:
N-(2, 6-dimethyL-4-nit~ophenyl)tetrahydro-3, 3-dimethyl-3H-oxazoloC,4-a7pyrazine-7(8H)-acetamide as an oily re~idue;
~ntermediate 122);
~J-(2, 6-dichlorophenyl)tetrahytro-3, 3-dimethyl-3H-oxazolo-~,4-~7pyrazine-7(8H)-acetamide as a~ oily residue (i~termedia~e 123); and N-(2-chloro-6-methyLphenyl)tetrahydro-3, 3-dimethyl-3H-oxa-~olo~,4-~7pyrazine-7(8~)-acetamide ai a~ oiLy residue (inter-mediate 124) ~2~L~3~S

E3~1I
A mixture of 23 8 parts of N-(2, 6-dichlorophenyl)hexahydro-3, 3 -dimethyl -1 -oxoimidazoL~, 5 -a7pyrazine -7 (8~) -acetamide a~d 256 parts of a hydrochloric acid solution 0 5N was stirred a~d 5 refluxed for 2 hours The reaction mixture was cooled overnight to room temperatu~e, alkalized and salted out with sodlum carbonate.
The product was extracted with trichlorom~thane. The extract was filtered and the filtrate was dried, filtered and evaporated. The r~sidue was crystallized from acetorli~rile, yielding 13, 6 part3 (64%) 10 of 3-(ami~ocarbonyl)-~-(2, 6-dichlorophenyl)-1 -piperazineacetamide;
mp. 180. 4-182 8C: (~termediat2 125), Following the 3an~e hydrolysis procedure, and sta~ting from the cor~e~pondirLg imidazo~, 5-~7pyrazine, there were also prepared:
X O
11 ~aryl CH -C-N
\~ 2 ~H
3~7~ m~. C
1 2 6 CO NHC H3 2, 6 - (C ~3 )2 C 6H3 127 CO NHZ 2 6 (CH3)Z-C6H3 190.1 1 28 CO-NHCH(C~3 )Z 2, 6-(C~3 )2 C 6H3 -12~ CO-NHCH(CH3 )2 2 6 3 13~ CO-NHCH2CH2OH 2, 6 Cl2 C6 3 131 CO-NHCH3 Z 6 3 167. 6 132 CO-NHZ 2 4, 6 (CH3)3 C6HZ
133 CO-NH2 2, 6 CE~ÇH3)~72 C6 3 134 CO-NHCH3 2-C1-6-CH3-C6H3 146.2 136 CO NHC~3 2, 6 (C~3)2, 4-NO2-C6HZ- 203.2 137 CO-NHCH3 2 4, 6-(CH3)3-C6H2 202.3 141 CO NHCH3 Z-CH3, 4-NO2 C-6 3 142 CO-NHCH3 5 -C1-2 C H3 -C 6H3 - 13 2 . 6 I 43 C O-NHCH3 2 -OCH3 C 6H3 - 1 69. 9 ?3~i Ex~IV
A mixtu:r~ of 8 5 parts of N-(5-fluoro-2-methylphenyl)tetrahydro-3, 3 -dimethyl 3H -oxazolo~3, 4-a7pyrazine -7 (8~) -aceta~nide and 105 6 part~; of hydrochloric acid solution 0 5N was stirred and reflu~ed for 2 hours The reactio~ mi~t~e was cooled to room temperatu~e The whole was a~lcalized with sodium carbonate and ~al~ed out. The proauct was extracted with trichlorometha~e. The extract waa washed with water, dried, filtered a~d evaporated.
The re~idue was purified by colum~-chromatography over silica gel using a mlxt~e of trichloromethane and methanol, saturated with ammo~ia (85:15 by volume) a~ eluent. The p~re fractioni w~re collected a~d the eluent waq evaporated. The residue was triturated in 2, 2' -o~ybic~propa~e. The product was filtered of and dried, yielding 4~ 4 part~ (59. 4%) of N-(5~fluoro-2AmethylpherLyl)-3-(~rdroxymethyl)-l-piperazineacetamide; mp 127. 7C (intermediata 145).
Followi~g the same hydrolysi~ procedure, a~d ~tarting from the corre~pondi~g oxazolo~,4-~7p~rrazine, there were also pre-pared:
2 0 N - (2, 6 -dime thyl -4 -rlitr ophenyl) - 3 ~ (hydr oxyme thy 1) -1 -piperazineaceta;nids; mp. 161. 8C (intermediate 146~, N (2, 6 -dichlor ophenyl) - 3 - (hydr oxyme thyl) -1 - piper azine -acetamide; mp. 117. 2C (intermediate 147); and N-(Z Achl~ro-6-methylphenyl) -3 ~(hydroxymethyl) -1 -piperaz~le -acetamide; mp. 116. 3C (i~terrnediate 148).

... . .. .... .

3~

~

~XV
To a stirred mixtlLre of 4. 56 parts of N-(Z, 6-dimethylphenyl)-3-(methylaminocarbonyl)-1-piperazineacetamide, 3 2 parts of sodium 5 carbonate and 36 parts of N,N-dimethyL~ormamid~ were added 6. 1 part~ of 1, 1 ' -(4-iodobutylidene)bis~4 -fluor obenzen~7. Stirring was co~at~ued for one hour at 75 G. The reaction mixture wa3 cooled and poured on~o 400 parts of water. The precipitated product was filtered off and di~solved iD 360 parts of dichloromethane. The solution was lO washed with 100 part3 of water, dried, filtered a~d evaporated The residue wa~ con~erted irLto the hydrochloride sal~ in 2-propanol.
The whole wag evaporated and the oily residue wa~ suspended three time3 in 1, l ' o~ybisethane. The la~:ter was decanted a~d the residue was allowed ~o stand for one hour with aceto~it~ile. The ~olid 15 precipitate waq fil~ered off, washed with warm acetonitrile and dried, yieldlng 7 44 part~ (79. 8%) of 4-C4,4~bis(4-fluorophenyl)buty~7-N- (2, 6-dimethylphenyl) -3 -(methylaminocarbonyl)~l -piperazine-acetamide dihydrochloride, mp. 228. 2C (compound 1).
Follow~g the ~ame N-alkylation procedure arLd using equi-20 valent amou~ts of the approprial:e ~tarting materials there were also prepared:

U
c~ ~ cr~ _, O
.- ~ ~ ~ o o o ~
~ . . ~.~
, O
~ ~ a ~ N
b ~ ~3 ~
o i ",~ V O
~: ~ ~ _~ o ~

¢ ¢
~ -- -- ~
u l l l l l l l l l l l l l l l ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ l x ~z~ ~
~ - ~ u v ~
~ l l l l l l l ~
`Z nJ , ~ ~ ~ ~ ~ ~ ~ ~, ~ ~ ~ ~ ~ ~ ~ ~ I
~~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ l ~ l ~ ~ æ ~ x o V O V ~ o V U ~ V
l l l l l l l l l l l l l l l l t~ ~ ~ ~J ~ N t~
1~3 ~ _ -;~ E ~ N

~ V ~ V V V C~ V
~ . I
___ X O Z ~ Z ~ Z 0~ 0~ C~ V~
V O ~ U V U V O
l l l l l l l l l l l l l l l l _ ~ ,,," o ~ ~ _ _ _ ~ o ~
~ , . . .
o ~
~, 3 ~
~ _ _ ___ .

r~ __ cr ~
o ~ _, ~ o ~ ~o _,, ~ ~ ,CO ~ C~
.~ M
. C~ J ~ 3 . . I
~ ~ o o ~ ~ o ~ ~ L~ o o ~ o ~ O O O O
~J ~ N ~1 ~
~ b ci ~ _ ~ _. _ ~
U ~ ~ o U

'~ ~ ' ~ ~ u ~ ~ o ~

~
~ c u o V `1~ O ~.
`

l----~

u '~ u ~ ~ v ~ v v o ~ v ~ v o u o '~
~ ~ o ~ x ~ ~ o ~ ~ ~ ~ v v X U ~ ~ ~Z ~
t~ o o o o o o o o ~ v ~ ~ v ~ v ~ '~
o ~ -- l l l u i--W r--~--~
l l ~
.. ~ r- ~ ~ ~ -- ~ ~ ~ ~ ~ r- co ~ o _ ~ o o -- -- -~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~

3~

O r~

. CO $
~ o __ ~
o~ i ~ ~ o ~ c~
~ rQ ~
C~l ~ 1 D ~ ~
. ~
V
î~
C~ Q) h n __ l l l l l l l ~ ~, ~, v '~ '~ V
~ U
o~ ~ x x X , ` `O ~D `O ~O `O ~ `O
Z ~
O ~ ~ __~
~' ~ ~

~ . o I~
o O ~
-~30~ O, ~o~z ~k~ ~o~

~ r 1~
....... . .. ._ ~
. ~
~ N
_ . . , . ._ 3~

~ - ~
~ o .,, _, ~ o CO ~ C2~
o _ CO o~ ~o ~ C~ Cl' CO
~ =l ___ O ~0~ ~ ~

, o ~ _ _ ~ O

~_," ,_ ~_ ~
! h , ._ .
,,~ ,. .. ..
, h .. ~ d _ _ o , _ _ _ _ _ _ "~ ~ ~ V
~ o ~ ~ ~--_ _ _ ~ _ V _ ~ I _ ~
X X ~ I $ ~
~ ~ ~ ~ ~ ~ ,~ ~ ~
Y ' Y Y ,,, '~ Y
C, h ~ t~
~ ~ ~ ~ V ~ d' ,, _ _ _ __ _ . ~ ~ O

. . ' V ~ ~ ~ ~ ~ ~ ~ d~

~Z~3 Exanlple XXXVI
A mixture of S part~ of 1,1 '-(5-chloropentylidene)bi3(4-fiuoro-be~zene), 5 parts of 3-(aminocarbonyl) N-(2, 6-dichlorophenyl)-1-piperazineacetamide, 2. 2 parts of sodium carbonate, 0. 1 parts 5 of potassilLm iodide and 120 parts of 4-met~yl-2-pen~anoAe wa~
stirred a~d refluxed for 24 hours, The reactio~ mixture wa~ cooled a~d purified by colurr~-chromatography (2x) ot~er silica gel u~ing first a mixture of trichloromethane and methanol (9~ 5 by volume) and then ~ mixture of trichlorometharLe and methanol (97:3 by volurne) 10 as eluents. The pure fractions were collçcted and the~ eluent was e~aporated. The residue was con~erted irLto the hydrochloride salt in acetonitrile ar~d 2-propa~oL, After s~irring for o~e hour a$ room temperature9 the salt was filtered off and dried, yielding 1 53 parts of 3-(amiT~ocarbonyl) -4-L4. 4-bls(4-fluorophesLyl)pentyl7-N-(2, 6-15. dichlorophe~yl)-l-piperazineacetamide dihydrochloride morLohydrate;
mp 206. 2JC (compound 49).
In a similar manner there was also prepared:
3-(arninocarbonyl)-N-(2, 6-dichlorophe~yl)-4-,~-ris(4-fluoro-phe~yl)methoxy7ethy~7-1-piperazineacetamide; mp. 185. 8G
20 ~compourld ;0).

A mixture of 7. ~ partY of 1,1 '-(4-iodobu~ylidene)bi~4-fluoro-berlzen~7, 5. 5 parts of N-(2-chlc3ro-~-methylphenyl)-3-~hydroxy-methyl)-l-piperazineacetamide, 4. 0 part~ of N,N-diethylethanamine 25 and 68 parts of N,N-dimethyLformamide wa~ stirred for 4 hours at ~bout 70G. The reaction mixture was cooled overnight to room temperature and the solvent was evaporated. The residue was taken up in trichLoro~etha~e. The organic phae~e was wa3hed with water, dried, filtered and e~aporated. The oily residue wa~ purified by 30 column-chromatography over ~ilica gel using a mixture of trichloro-methane and metha~ol (95:5 by volume) as eluent. The pure fractions were collected and the eluent waq evaporated. The oily residue 901idiied on triturating i21 2, 2'-oxybiapropane. The product was iltered off a~d dried, yielding 3, 21 parts (33 1 %) of 4-~4,4-bis(4-35 fluorophenyl)butyl7-N-(2-chloro-6-methylphe~yl)-3-(hydroxymethyl)_ 36 1 -piperazineacetamide; rnp. 149 8~C ( compound 51).

~12~395 .. __ ~ a U~
.~ ~ ~o o I
~- ~ ~ ~ co r- o ~ ~_ 0 .__ . _ I
td h ~ ~ I
~ O
O ~ al ~ ~ ~4 aJ ~ o ~
U~ ~ t~ ~ 2 ,C~
~ ~, C '~
~; E~
~, ~

E - ~ o Z Z

b ~ Y. ~ ~ ~ C V

oy .
C ~
Q~ U ~
"z~ U ~ o C~ ~ I X o ~ ~ ~ Z ~ ~ Z ~ .
o * ~ ~ ~ ~ o o o o o o , h ~ o ~ " Y

~ 0 __. ~
~ ~ , ~
:~ ~ -~ X~ I ' ~1, , ~ , , , , ~ ~ I
~ 3 ~ ~ ~ o 2~ h U o t~ W, ~o, ~ '~
~_ ~ ~ ~~ ~, ~ ~ ~, ~ ~ ~ ~ ~
." ~ ~ d' ~ ~ ~~ dq I ~ ~ I ~, ~ .,.............. ~ X ~ ~ , -o ~ ~ Y Y~
t~ t4 h h ~ o h d' O

~ .~ CO o U~ ~ o ~
o_. o _, _, o o _ , ~ ~ I

O ~ , ~ , X
~ ~n .9 ~1 5 ~ O D
j l~ E
~ ~ o o s~
~ ~ V ~ U
~ o o ~
.. ~ o~ , ~ ~

~ ~ ~ ~ ~ ~ ~ t~a l x z ~ z o ~
i I
V,, ~ ~ ~
l ~ ~ ~, , ~ , ~
ll a ~3 ~ I ~ o ~ æ~

. ~, x~
,. . . .
0 5 ~O `O ~O ~O ~o ~o ~ `4 Exarnple XXXVIII
A mLxture of 2 5 parts of ~2-naphthaLenyloxy)methy~7oxirane, 3. 31 parts of 3-(arninocarbonyl)-~-(2, 6-dichlorophe~Lyl)-l -pipera-zineacetamide, 45 partq of benzene arld 20 parts of methanol was 5 stirred first for 3 hours at room temperature and ~urther for 30 hour3 at reflux The reaction mix~ure wa~ cooled and purified by column-chromatography over silica gel u~ing a mixture o trichls~o-methane and methanol (90:10 by volurne) a~ eluent. The pure fraction3 were collected and the eluent was evaporated. The re~idue wa~
10 conrerted into the hydrochloride salt in Z-p~opa~ol and acetonitrile.
Upon stirrirlg overnight, the salt was filtered off and dried over week-e~d, yielding 1, 39 parts (Z3 %) of 3^(amir~ocarbonyl)-N
(2, 6-dichloropher~yl)~-~-hydraxy-3-(2-naphthalenyLoxy)propy~7-l_piperazineacetamide dihydrochLoride mo~ohydrate; mp. 15~. 3C
15 (compound 69).
Is~ a similar manner there was also prepared:
3 (aminocarbonyl)-4-L4, 4-bis(4-fluorophenyl)-2-hydroxybutyl7-N-(2, 6-dimethylphenyl~-1 -pipera2~eacetamide; mp. 1l0 2C
(compou~d 70~
20 E~eample XXXIX
A mixture of 4 3 part3 of 4,4-bis(4-fluorophe~yl)cyclohexanone 4. 35 parts of 3-(am~ocarbo~yl)-~3:-(2, 6-d~ethylphenyl) l-pipera-zineacetanlide, 1 part of a solution of thiophene in etha~ol 4% and 150 parts o 2-me~hoxyethanol wa3 hydrogenated at normal pressure 25 a~d at room te~perature with 2 part~ of palladiu~n-on-charcoal catalyst 10%. After the calculated amou~t of hydrogeQ was taken up, the catalyqt was filtered off and the filtrate was evaporated. The re~idue waq purified by column-chromatography over silica gel using a mi~cture of trichloromethane and meth~ol (97:3 by volume) aq 30 eluent, The pure fractiona we~e collected a~d the eluer3t was evaporated, From the re idue the isomers were eparated by HPLC
u~g a mi cture of methylbenzene a~d ethanol (95:5 by volume) as eluent. The fraction containing the B^isomer was collected and the eluent was e~raporated~ Theresidue wa~ suspended in petroleumether.
35 The product was filtered o~f and dried, yielding, ater drying in vacuo ~2~3~

at 145G, 1,73 part~ of (B)~3-(aminocarbonyl)-4-~4,4-bis(4-fluoro-phe~yl)oyclohexy~-N-(2, 6-dimethylphenyl)-1-piperazineacatamide;
mp. 21Z. 1 C (compound 71), ~L
A mix~ure of 4. 05 part~ of 2-chloro-N-(2, 6-dichlorophe~yl)-acetamide, 50 6 parts of 1 -C4,4-bi~(4~1uorophenyl)butyl7-2-piper-azirlecarboxamide, 2. 94 parts of N,N-diethylethanamirLe and 63 part~ of N,N-dimethylformamide wa~ stirred for 5 hour3 at 70~C.
The reastiorL mixture wa~ poured onto ice-water. The precipi~ated product was filtered off and dissolved in dichlorometha~e. The ~olutioxl was washed with water, dried, filtered and evaporated.
The residue wa~ p~rified by colusn~-chromatography sver silica gel using a mixt~Lre of trichlorom~tha~e and methanol (95:5 by volume) aq eluent. The pure fractions were collected and the elue~t was evapora~ed. The residue wa~ convested into the hydrochloride salt 2-propa~olle a~d 2-propanol. The 3alt wa3 filtered off and s~irr ed f or 30 minute s in 1,1 ' -oa:ybisetha~ae , yielding 4. 54 parts of 3 ~ inocarbonyl) -4-~4, 4 -bis~4-fluor ophenyl)butyl7 -N _(2, 6 -dichlorophe~yl)-l-piperaziI:Leaceta~nide dihydrochloride monohydrate;
mp. 182, 7G (compound 72).
Following the ame N-alkylation procedure a~d u~ing equi-valent amou~t~ of the appropriate starti~g materiaL~ there were also prepared:

_.
~ _ ~ , o ~
o o .~ CO ~ ~ o ~ _ -' ~ ~ ._ t` ~ CO _ ~ _ _ ~ ~ _. ~ _ ~ ~ ~ ooo ~ ~ ,~
o o ~ V ~ V
V ~ V
~J trJ D-- 8 ~ ~ 3 ~4 ~ D t~
rS~ al N
__ ~ _I
I I 1 1~ 1 I I I ~ '1 r~ I I I _ I
V~ ~ I U
U ~ V t~ U ~ ~0 0 U

~ ~ v ~o~ $ ~ o o v U O v ~ æ~ ' ~O ~D ~ W ~ ~ ~ ~0 ~ ~ U ~ ~ ~ U O O
Z~ ,~
0~ __ s ~ 1 x ~
_~
J
I I ~:: I I I I I I , I ,, ~, , , ~ J ~ ~ M ~ t.) V X Z: Z: O Z Z~ Z Z; Z; Z~ Z Z; :Z; Z ' O O O O O O O O O O O O O O O C) O -t~ O O V O V t) O U O ~ V W ~ V
, , , l I l I . l l l l l l I , rr~

. . . ~

~ ~ ~ ~ x -~ l '~
tJ ~
- - ~
~ $

v v v o o o ~ v ~ v t~
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ l ~ l ~~
V $ ~
~ I t~ V~ V V~ V, y ~ y v ~q~O I ~ I I I I I I I I I I I
U ~ 'r ~ ~ 'r 'r ~ 'r ~ ~ ~ ~ ~ er O ~ ~ ~ ~ O --. ~ ~ ~ ~n ~ r-. _U._ _ ._ . .. _ .

~L2~L~3~5 e o c ~ O O ~i ~i ~ _ ~3 ~i I e~ O I ~ I I I ~ ~ I
y ~ ~u~) t~i CO ~ O 1 ~1 2 ~ Z ~ O ~ ~ ~ O `O ~l ~ ~i ~
__ .. , _ _ O O O O O O O
O
1 4~ 4~ 0 Ui 4 a ~ ~ e~

' ' ~ v ! '~ J~z~ U~z~
_. X~ ~ ~ U ~ V` ~ V
n~ ~ V U ~-~ , ~ V ~ t~ v r ~ ~ ~ ~ ~ ~O ~ o ~ ~
~ ~~ i rY ~
' ~ ~
__ ~;i o '~ U~
!x ~ o~x~
~ Z ~ ~ Z ~ ~ ~ Z ~ Z Z Z
o o o o o o o ~ o o ~ o o o o o o o , . . . . ~ . .

~ ~ ~ ~ ~ ~ ~ x ~ ~
U O U ~ U ~ U
li v l-- - ~
l l l l l l l l l l l l l l l l l l ~ ~ u ~ u v ~

~ w ~
i~X V ~ y y y y ~ y y o y y o Ul ~ y y l l l l l l l l l ~ l l l l l l l l ~, o ~ o~ ~ o ~ o ~ C~ o o o . _. .

~Z~3~

o ~
_ ~_ o _ ~ ~ ~ .12 ~n ~ ~ ~ _~
_ . . __ a S~ ~ ~
~o ~_ h ~
æ v ~
.. ' ~ ~ ~ ~n ~
X~ ~ ~=
~ Z X ~ ~ O ~
O ~ V
~d _ ___ _ I

~ ~ V y ~
a~ ~o~Co~ Co ~ ~ U~
o ~
CO ~ o _ C~ o o O _ _ ~2~3~

~cample XLI
A rs~ ure o 24. 0 par~s of ~ -methyl-4~(pherLylmethyl)-2-piperaz~emethanol, 27,3 parts of 2-chloro N-(2, 6-dlmethyLphenyl)-acetamide, 25.a parts of sodium carbo~ate, 0.1 parts of po'cassiu~
5 iodide a~d 180 part~ of N,~ dimethylormamide was stirred for 18 hours at 60C. The reaction mi~t~re was poured onto water and the product was extracted wi~h dic~loromethane. The ex~ract was washed with wa~er, dried, f.iltered and evaporated. The reiid~e wai pu~ified by colu~nn-chromatography o~er ~ica gel UsL~g a mixture of tricblorome~hane and methanol(90:10 by volu~ne) as elue~t. The pure fractions were collected and the eluent wa3 eYaporated. The re3i-due was crystallizedfroml,l'-oxybisethane, yieldi~g 35. 19 parts (8~ . 8 % ) of N - (2, 6-d~ne thylphe:nyl) ~2 - ~1 -hydroxyethyl) ~4 - (phe~yl -me~yl)~l-piperazineace~ mide; mp. 148.8~C.(compound 113).
Follown~g ~he same N-a~kyla~o~ procedure a~d using equi-~aleRt amo~ts of the appropr~ate starting m~terials t}lere were al30 prepared: O 1 ~3 C ~ N ~ Y C m ~ ~ C N

- -- ~
! G om~ . Ste re oohemically Ba se or mp .
pou~d X CmHzm iso2nerio form Salt form C
, ,, , _ ___ _ _ 1 114 2 -C~2S )H CH2 base I _ I
, 115 2 CH2OCH3 CH2 ba~e I _ 116 2-C~:~N~C;H3~2 CH2 2HGl 240 117 2-C;H2oC2~5 CH(CH3~ A+}~ base 118 2-CH2O(;2H5 CH2 ! base _ 11 9 2 -CH2C ONH2 CH2 ba~e 120 2-cH(cH3)ocH3 C~2 B base C II~C ~1~ I CC H~ ~ l~z ba s c ~2~3~

A mi~ture of 3 . 7 part~ of 1-~, 4-bis(~-iluorophenyl)but~ 2-pipera7.i~ecarboxamide, 2,3 ~arts of 3-chloro-N-(2, 6-dimethyl-phe~yl)propa~amide, 2.1 parts of sodilLm ca~bo~ate, 0.1 part3 of potassium iodide and 200 parts of 4~mel:hyl~2-pe~tanone was s~rred and refluxod for 20 hour~ U5irLg a wate~-3eparator, The reactio:~L rnixture wa~ cooled to room temperature and filtered.
The filtrate was evaporated The oily residue was puri~iedby column-chromatography over silica gel usiDg a mixture of trichloro-m~ Le and methaDol (95:5 by ~rol~e) as eluent. T~e pure frac~o:~s were collectedand the elus:tltwas e~aporated The residue 301idi~ied on triturati~g ~ 2, 2' -o~ybispro~a~e. T~e product was filtered off a~d dried, y~eldi:ag 3 . 87 par~ (7û. 8%) of 3 -(ami~ocar~onyl)^l-bis(4-~uorophenyl)buty~7-N-(2, 6-dlmeth~lphe~lyl)_1-piper~
azi~epropa~amide; mp. 12059C. (cornpou~d 122) Following ~che ~am~ N-alkylation procedure and usi~g eaui~ralen.t amou:~ts of the appropria~e s~:ar~g materials ~shere were al80 prepared:

7b . ..
~ ', ~ ~ , ~ ~ , .. ~ ~ ~ --' q~ ~ ~ ~ ç~ ~ ~ ~ ~ ' r- ~o _ o u L~ ~ r~ o ~ c~
r~
.___ O~ o O
o ~
~o ~,,, ~ 0 ~ n v ~ - - ~l ~æ~, X~J '~ '~ ' ~æ . ., U ~ U ~ U
_. ~ , U ~ V ~ ~J U
~ ~ ' Y ' ~ ~ U ~ Y v '~ v ~
~ ~ O ~ V

$ /=\ ~ ~ , , ~ , , ~ . ~ ' .. ' o . , , 1~

__ ~ _ ~1 ~ ~ U ~ V O ~ U ~ O C) --__ ~
~ 11 O ~Z; 0~ Z ~ Z Z; ~; ~ Z Z Z Z
~K ~ ~ ~ O O O O O O O O O O O O O O
y V V V ~ ~ V ~
~ ~ ~ ~ ~ ~ ~ ~ ~ ~I ~ ~ ~ ~ ~ ~ ~ I
... ., ....... ,.. . , ... . .. ~ ~

~ 0 V C`
. ~ ~ ~ ~ ~ ~ ~ ~ o o O ~ ~ ~ ~ O ~ ~ ~ O d' O O
. ~ ~

~ o ~

__ ~ ~ ~ 0~ æ~

q U ~ q ~
U ~ V ~ Z
_~ .

~ ,~ ~ ~ æ ~
t, ~ V 0 5~ V

x ~ o z o ~ z o o Q ~, o 3:~ o ~ o ~ O
~ Y '? Y " '? '? V
o ~

_ _ ~ . . .

-- . .

~2~L~3~5 Example XLIII
Durirlg 5 hours, ga3eous hydrogen chloride was bubbled through a stirred and refllL~ing rnixture of 5 part~ of 1-~4-bi~ 1uorophenyl)_ but~7-4-~2-~2, 6-dimethylphenyl)amin~7 Z-oxoethy7-Z-piperazine-carboxylic acid and 200 parts of absolute ethanol. After ~tanding o~rer~ight at room temperature, the reaction mixture was evaporate~
The residue wa~ taken up in 200 parts of water and alkalized with sodium hydroxide The product was extracted twice with 80 parts of 4-methyl-~-p0ntanone, The combined extract~ were dried, filtered and evaporated. The reqidue was puri~ied t~;TJice by column-chromato-graphy over ~ilica gel using a mixture of trichloromethane and methanol (90:10 by volume) as eluent. The pure fractions were collected and the eluent wa~ evaporated The reiidue was converted into the hydrochloride salt in ethanol and 2^propanol. The 301~feIlt wa~ evaporated a3ld the semi-~olid re3idue was dissolved in a mixture of 16 parts of 2-propa~one and 2 parts of water The whole was evaporated. The ~olid residue was pulverized and dried, yieldlng 2. 37 parts (40%) of ethyl 1-~4, 4-bis(4-fluorophenyl)butyl/4-/2-~r2,6-dimethylphenyl)amirLo7-2 -oxoethy~7-2 -piperazinecarboxylate ZO dihydrochloride hemihydrate; mp. 118. 8C (compound 154).
Examole XLIV
A mixture of 52 part~ of ethyl 1-/4, 4-bi_(4-fluorophenyl)but~
4 -,~ 2, ~ -dimethylphenyl)amino~7 -2 - oxoethy~7-2 -piperazine -carboxylate and 600 parts of co~cerltrated hydroc~loric acid was Z5 stirred for 8 hQurs in a boilin~ wates-bath The reactiorl mi~Y~ure was concentrated to a volurne of about 200 parts. Th~ supernatant aqueou_ phase was decanted and the oily residue was dis~ol~ed in 400 parts of 2-propanone and 500 parts of water. The whole was neutralized by the portionwise addition of ~odium hydrogen carbonate.
The 2-propanone was evaporated on a Rotavapor. The zqueous phaqe wa~ decanted arld the residue waq triturated in warm 4-methyl-2-pentanone. .9~ter cooling, the product waa filtered off and dissolved in 200 parts of methanol while heating. After cooling, 250 parts of water were added and the whole waa stirred for a while The solid product was filtered off and crystallized from acetonitrile, yielding, s after drying in vacuo for 3 hour~ at 110C, 16. 32 parts of 1-~,4-bis(4-fluo~ophenyl)butyl7-4-L2-L(2, 6-dimethylphenyl)a~ino~-2-oxoethy~-2-pipera:zlnecarboxylic acid; mp. 186. 5C; (compound 155).
Example XLV
To 1 part o-f a solution of 2 parts of ~:hiophene in 40 part~ of etha~ol were added 3, 4 parts o~ 4-~, 4~bis(4-fluorophenyl)buty~7-N-(2, 6-dimethyl-4-slitrophenyl)-2-(hydroxymethyl)-1 -piperazine-acetamide and 120 parts of methanol. The whole is hydrogellated at ~o~mal pre~ure a~d at roosn temperature with 2 pa~ts of plat;num-on-charcoal cataly~t 5 %, After the calculated amou~t of hydrogen was talcen up, the cataly~t was filtered off and the filtrate was e~aporated. The oily residue was puriied by colu~ chromato-graphy over silica gel u~ing a mixture of tri~ hloromethane and me$hanol (90:10 by volume) as eluent. ~he pure f~action~ were col-lected and the eluent wa~ evaporated. The oily residue ~olidified orL cooliLlg ~ a Z-propanone/CO2-bath, The product was dried, yieldi~lg 1 73 parts (54~ f N-(4-ami~o-2, 6 dimethylphenyl)-4~
~4, 4 -bis (4 ~ fluor ophenyl)buty~7 -2 (hydr oxymethyl) -1 piperazine -acetamide; mp. 85. Z~C (compound 15b).
~0 I~ a sinlilar manner there were also prepared:
3-(aminocarbo~yl)-N-(4-ami~o-2, 6-dimethylphenyl)~4-L4, 4-bis(4-fluorophenyl)buty~7-l-piperazi~eacetamide; mp. 114. 4C
(compou~d 157), N-(4-amino-2, 6-dimethylphe~yl~-4-~, 4-bis(4-fluorophenyl)-bu~yl7-3-(hydroxymethyl)-1-piperazin~acetamide; mp. 81. 3C
(c ompouDd 15 8);
N-(4-amino-2-methylphenyl)-4~ -bi~4-fluorophe~yl)butyi7-3-L~methylasni~o)carbony~7-1-pipera~ineacetamide; xnp. 86. 2~G
(c ompound 15 9~;
3-(~minocarbo~yl)-y-(4-amino-2, 6-dichloroph~nyl)-4-,~, 4-bi~(4~fluorophenyl)buty~7~1-piperazineacetamide dihydrochloride dihydrate; mp, 196, 3C (compound 160); and 3 -(aminocarbonyl) -N - (4 ~amino-5 -chloro - 2 -methoxyphenyl~ -4 -~4,4-bis(4-fluorophenyl)butyl7-1-piperazi~eacetamide; mp. 189. 3C
(compoulld 161), ~ 3~

XLVI
To 1 part of a solution of 2 part~ of thiophe~e in 40 paIt~ of ethanol were added 3 parts of 4-~, 4-bis(4-fluorophenyl)buty~7-N-(2, 6-dimethyl-4-nitrophenyl)-2-~methylamino)carbony~
piperazineacetamide and IZ0 parts of metha~ol. The whole was hydroge~ated at normal pressure and at room temperature with 2 parts of pallatium-on-charcoal catalyst 10%, After the calculated amou~t of hydrogen was take~ up, the catalyst wa~
filtered of~ and the filtrate was e~raporated. The residue was purified by colu~chromatography over sillca gel usi~g a mixture of t~ichloromethane and methanol (95:5 by volume) a elue~t. The pure fraGtions were collected and the eluent wa~ e~raporated.
T~e residue w~s ~usp~nded i~ 2, 2'-o~ybi~propane, yield~g 2. 14 parts of N -(4 -amino -2, 6 -dimethylphe~yl) -4 -~4, 4 -~i 5 (4 -fluor opheny}) -buty17-2-~methylami~o)carbo~yl7-1-piperazineacetamide;
mp, 111, 7G (compou~d 162).
Irl a ~imilar man~er there were also prepared:
N-(4-amino-2, 6-dim~thylphenyl)-4-~, 4-bis(4-1uoropherlyl)-butyl7-3-~methylamino)carborLy~ piperazi~eacetamide;
mp. 88. 7C (compourLd 163); and 3-(aminoca,rbo~yl)-N-(4 a~xli~ophenyl)~ , 4-bis(4-fluoro-phenyl)buty~7-l -piperazineacetamide morlohydrate; mp. 90. 1 C
(compou~d 164) Example XLVII
A mixtuse of 5. 5 parts of 3-(aminocarbonyl)-N-(4-amino-Z, 6-dimethylphenyl)-4-C4, 4-bi~(4-fluorophenyl)buty~ piperazine-acetamide, 8 part~ of 2-propanone, 1 part of a solution of thiophene iu ethanol 4% and 120 parts of methanol was hydroge~at~d at ~ormal pre~sure and at room temperature with Z parts of palladium-on-charcoal cataly~t 10%, After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated.
The reRidue wa~ ~uspended in 2, 2' -oxybispropane. The }r oduct wae filtered of:E arad dried, yielding 4, 5 parts of 3-(aminocarbonyl)-4-,~, 4-bis(4-fluorophenyl)butyl7-N -r/2, 6 -dimethyl-4 -/~(1 -methylethyl) -asnino1pheny~'-1 -piperazineacetasnide monohydrate; mp. 100. 7C
36 (compo~d 165).

~2~a~3~5 Exa~ple XLVIII
A mi~ture of 5 5 parts of 3-(aminocarbonyl)-N-(4~amino-2, 6-dimethylphenyl)-4-~4, 4-bis(4-fluorophenyl)but~J~7-1 -piperazine-acetamide, 1 part of a solution of thiophene ~n ethanol 5~, 3 parts of poly(oxymethylene) and 120 part~ of methaslol was hydrogenated at normal pre~ure and at room temperature with 2 parts of palladium~on-charcoal cataly~t 10% After the calculated amou~t of hydrogen was taken up, the cataly~t was filtersd off and the filtrate waq evaporated. The residue was ta3~en up in a dilu~ed hydrochloric acid ~olution a~d the whole was washed with Z, 2'-oxybi~prop~e, The a~ueouq phase was a~Xalized a~d extracted with dichloromethane The cambined organic phase~ were washed with water, dried, filtered and evaporated. The residue was co~verted into the hydrochloride ~alt in acetonitrile and 2-propanol.
The salt was filtered off and crystallized from 2-propa~ol, yielding 2. 86 part3 of 3-(aminocarbonyl)-4-~,4-bis(4-fluorophenyl)buty~7-N-~-(dimethylamino)-2, 6-dimethylphe~y~7-l -piperazineacetamide trihydrochloride monohydrate; mp. 194. 5~C (compound 166) In a similar manner there was al~o prepared:
3-(ami~ocarbonyl)-4-,~, 4-bis(4-fluorophe~yl)buty17-~
(dimethylamino)phe~y~7-1-piperazi~eacetamide mo~ohydrate;
rnp. 96. 3 ~ G (c o~npou~d 167 ).
Exam~le IL
To a stirred ~olutiorl of 5. 5 part~ of 3-(ami~Locarbonyl)-~-(4-am~Lo-2, 6-dimethylphenyl)-4-~, 4-bis(4-fluorophe~yl)bu~y~
piperazineacetamide in 70 parts of ace~ic acid was added dropwise a solu~ion of 1. 62 part~ of potas ium i~ocyanate i~ Z0 parts of water Upon completion, 3tirring at room temperatu:~e was co~ti~ued for 30 mir~ute~ Upo~ standing overnight at room temperature, the reaction mixtu~e was evaporated. Water was added to the residue and the product was extracted with dichloromethane. The extract was wa~hed with water, dried, filtered and evaporated. The residue was puri~ied by col~nn-chromatography o~er silica "el u~ing a mixture of trichloromethane znd methanol (90:10 by ~olume) as eluent. The pure fractions were collected and the eluent was evaporated The residue was crystallized from acetonitTile, yielding 2 55 part~ of 3 (aminocar~onyl)-N~ amirocarbonyl)-amin~7-2, 6-dimethylphenyL7-4-,~, 4-bis(4-fluorophenyl)buty~7-l~iperazineacetamide; mp, 142.5C (compou:ndl68~.

A mlxture of 5. 5 parts of 3-(aminocarbonyl) N-(~-amino-2, 6-dimethylphenyl) -4 -~4, 4 -b i ~(4 -fluor ophenyl)buty~ pipe r azine -acetamide, 1. 82 par~st of propa~oio a id anhydride and 90 parts 10 of methylbe~zene wa stirred alld refluxed for Z0 hours. Water wa~ added to the reaction m~ture and the layer~ were separated.
The organic phase -~ras wa het with a sodium carbonate 801Utio}:L
and with water, dried, filtered and evaporated. The residue was purified by colum~chromatography o~,er silica gel u~ing a mi~tura 15 of trichloromethane alld methanol (95:5 by volume) as eluent.
The first fraction was collected and the eluent was evaporated.
The residue wai ~uspeIlded i21 Z, Z'-oxybispropane. The product was filtera~d off and crystallized frcm acetonitrile9 yielding 1. 38 partC~ of N~ aminocarbonyl)-4-~4,4-bis(4-fluorophenyl)-~O buty~ piperazi~7acety~7amin~ -3, 5-dimethylphenyl7-propanamide mo~ohydrate; mp. 136G (compound 1 69).
xamPle ~ LI
A mixture o~ 4 parts of 3-(ami~ocarbonyl)-4-~3, 3-bis(~-fluoro-phenyl)-2-propeny~7-N-(2, 6-dimethylphenyl)-1 -piperaz~eacetamide 25 and 120 part3 of methanol was hydrogenated at normal pre~sure a~d at room temperature with 2 pa~ts of palladium-on-charcoal catalyst 10%. After the calculated amo~nt of hydrogen wa3 take~ up, the catalyst wa3 filtered off and the ~iltrate wa~ e~aporated. The residue waa puriied by colu~s~-chromatography over qilica gel uqing a 30 ~nixture of trichloromethane and methanol (90:10 by volume) as eluent. The pure fractio~3 were collected and the eluent was evaporated The re~idue was su~pended in 2, 2' -oxybi3propane. The product was filtered off and dissolved in acetoni~rile The solution was filtered a~d the filtrate was evaporated. The residue waq crystallized 35 from 2, 2'-oxybispropa~e The protuct was filtered of~ and dried, 3~3 yielding 2. 21 part3 of 3-(aminocarbonyl)-4-L3-, 3-bis(4-iluorophenyl)-propy~7 -(2,6-dimethylphenyl)-I~piperazineacetamide;rnp. 143 2C
(compou~d 170).
Example LII
A mixture of 4. 45 parts of 5~chloro-l, 1-diphenyl-2-pentanone, 9, 94 parts of 3 -(an~inocarborlyl) -N -(2, 6 -dichlorophenyl) -1 -pipera-zineacetamide and 90 partq of N,N-dimethylormamide w~s 9tirred for 48 hours at 60~C and e~aporated. The residue waa taken up i~ water and alkalized wlth ammonia, The product was extracted twice with di-ohloromethaz~e, The combined extracts were washed with water, dried, filtered and evaporated. The residue was purified tw~ce by column-c~omatography over ~ilica gel U5i~1g a m~ture of trichloromethane ar~d metha~ol (95:5 by volum~) aq eluent. The pure fraction~ were collected and the eluent wa evaporated. The residue wa~ taken up i~ 2, ~'-oxybispropane and allowed to starld for 10 day~.
The product WâS filtered o and dried at the air, yielding 0. 32 parta (3. 7 ~) of 3 -(aminocarbonyl)-N-(2, 6 -dichlorophenyl) -~-(4-oxo-5,5-diphenylpentyl)-I-piperazineacetamide monohydrate;
mp. 91. 6C. (compound 171), ~
A mixture of 3. 3 parts of ethyl 1 -~4,4-~is(4-fluoropher~yl)buty~7-4 -L~ 2, 6 -dichlor ophenyl)amin~7 -2 -oxoethy~7 -2 -pipera2i~e -carbo~ylâte and 60 partQ of a ~ydrochloric acid solutio:n 12N was stirred for 8 hour3 at 100C in an oil-bath. 2-Propano~e wa~ added whereupo~ a solution was obtained: The pH was adjusted to 5 with ~odium 'nydroge~ carbonate and the Z-propanone was evaporated:
a sticky oil i~ water wa remained. The a~ueou~ phase was decanted aIld the sticky oil was taken up in 24 parts of 4-methyl--2-pentanone while warming. The ~olid product was filtered o~ and boiled in 120 part3 of acetouitrile. A4ter cooling for a while, the less pure product was filtered off and the filtrate was coolsd. The product was filtared off and dried, yielding 0, 31 parts o~ ,4-bij(4-fluorophenyl)buty~7_ 4-/2-~2, 6-dichlorophenyl)amino~-2-oxoethy~-2 -pipe~azinecar-boxylic acid; mp, 204, 3C (compound 172), ~L03~S

To a stirred solution of 3 parts of 3 -(aminocarbonyl)-4-~, 4-bis(4-fluorQphenyl)buty~7-N-(2, 6-dimethylphenyl)-l -piperazine-acetamide in 24 parts of etha~ol wa~ added a solution of 0. 94 parts of (~) 2, 3-dihydroxybutanedioic acid in 24 parts of ethanol.
The whole waQ eva?orated and the oily residu~ wai dissolved in warm 4-methyl-2-p~ntanone, After cooling to 0~:;, the product wa~ fil~eret o~f and dissolved in 2-propanoneO 0. 2 Part~ of 2, 3-di~ydroxybutanedioic aoid were added and upon the additio~ of 4-methyl-2-pentanone, the product was precipitated. It waq filtered off a~d dried, yieldir~g 0. 8 part3 o~ (+)-3-(a~ninocarbo~yl)-4-~4, 4 bis~4-fluorophenyl)buty~7-N-(Z, 6-dirrlethylphenyl)-1 -piperazine-acetass~ide ~-(R~, R3~7-2~ 3-dihydroxybutanedioate (2:3) mono-hydrate, mp. 78 1 C (c om~pound 173 ), Example LV
A solll~io~ of 3 parts of 3-(aminocarbo~yl)-4-~4,4-bis(4-fluoro-phenyl)buty~7-N-(2, 6-dimethytphenyl)-1 -piperazineacetamide in 80 parts of 2-propanone was added to a soLution of 1. 9 parts of (Z)-2-butenedioate in 40 parts o 2-propanone: 510wly CryqtalliZatiOIL
~he product was filtered off a~d r~crystallized twice fro~ 2-propanol a~d once from 2~propanon~, yielding 1. 56 parts (39%) of 3 (ami~ocarbonyl)-4-~4, 4-bis(4-fluorophenyl)buty~7-N-(2, 6-dimeth~
phenyl)-l -pipera. ~eace~amide (Z)-2-butenedioate (1: ) rnoIlo-hydrate; mp. 119. 6C (compound 174).

Claims (8)

CLAIMS:
1. A process for preparing a chemical compound having the formula (I), the stereochemically isomeric forms and the pharmaceutically acceptable acid addition salts thereof, wherein R1 is a member selected from the group consisting of hydro-gen and lower alkyl;

X is a member selected from the group consisting of hydroxy-lower alkyl, lower alkyloxylower alkyl, aminocarbonyl, mono- and di(lower alkyl)aminocarbonyl, carboxyl, lower alkyloxycarbonyl, (aminocarbonyl)lower alkyl, [mono- and di(lower alkyl)aminocarbonyl]-lower alkyl, carboxylower alkyl, (lower alkyloxycarbonyl)lower alkyl and (hydroxylower alkyl)aminocarbonyl;

m is the integer 1 or 2;

R2 is a member selected from the group consisting of hydrogen and lower alkyl;

R3, R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower alkyloxy, halo, trifluoromethyl, lower alkylcarbonyl, aminocarbonyl, lower alkyloxycarbonyl, cyano, amino, mono- and di(lower alkyl)amino, (lower alkylcarbonyl)amino and (aminocarbonyl)amino, while R3 may be nitro or R3 and R4 may both be nitro; and R is a member selected from the group consisting of a radical having the formula (a) wherein Ar1 and Ar2 are each an aryl radical; and a radical having the formula -Alk-Q (b) wherein Alk is an alkanediyl radical or a lower alkenediyl radical, said lower alkanediyl radical being optionally substi-tuted by a hydroxy- or a lower alkyl radical; and Q is a member selected from the group consisting of aryl, aryloxy, diarylmethoxy, 2,2-diarylethenyl, diaryl-methylcarbonyl, arylcarbonyl, mono- and diaryl-aminocarbonyl, diarylmethyl, the methyl moiety in said diarylmethyl group being optionally substituted with a cyano-, an aminocarbonyl-, a mono- or di-lower alkylaminocarbonyl- or a lower alkyloxy-carbonyl radical, arylamino, said amino moiety being optionally substituted with an aryl-, an arylcarbonyl-, a loweralkylcarbonyl-, an arylsulfonyl- or a lower alkyl-sulfonyl radical, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, being optionally substituted in the 5- or 6-position by halo, 10H-phenothiazin-10-ylcarbonyl, being optionally substituted by a halo atom, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl, 1-aryl-1,3-dihydroisobenzofuran-1-yl, and 2,2-diaryl-1,3-dioxolan-4-yl;

wherein aryl is a member selected from the group consisting of phenyl, substituted phenyl, naphthalenyl, thienyl and pyridinyl, said substituted phenyl having from 1 to 2 substituents, each independently selected from the group consisting of halo and -(halo-substituted phenyl)carbonyl;
characterized by 1) reacting a reagent of formula R-W (III) or (V) or the corresponding carbonyl-oxidated form thereof with a pipera-zine having the formula (II), respectively the formula (IV), in a suitable reaction-inert solvent and, in case the carbonyl-oxidated form of a reagent of formula (III) or (IV) is used as reagent, in a suitable reductive medium, said W being a reactive leaving group; or 2) reacting a carboxylic acid derivative (VI) (VIII), wherein R6 is hydroxy, lower alkyloxy, aryloxy, amino, chloro, bromo or iodo, with a reagent of formula (VII) (IX) in a suitable reaction-inert solvent; or 3) reacting a diamine of formula (X ) or (XII) with a reagent of formula (XI) or W-CH2-CH2-W' (XIII), wherein W and W' represent each a reactive leaving group and wherein the 1,2-ethanediyl radical in (X) or (XI) and in (XII) or (XIII) are optionally substituted with a lower alkyl radical, said reaction being carried out in a reaction-inert solvent; or 4) reacting an amine of formula (XV) or R-NH2 (XVI) with a reagent of formula (XIV) or (XVII), in a reaction-inert solvent, said W and W' representing each a reactive leaving group; optionally converting the compound of formula (I) obtained following one of the hereinabove described procedures into another compound of formula (I) by a functional grouptransformation-procedure, which procedure is selected from the group consisting of a) reacting a compound of formula (I) wherein X is a carboxyl function with a suitable alcohol, ammonia or mono- or di(lower alkyl)amine in a suitable acidic- or alkaline medium or with a suitable lower alkylhalide in alkaline medium, b) hydrolyzing a compound of formula (I) wherein X is a lower alkyl-oxycarbonyl-, an aminocarbonyl or a mono- or di(lower alkyl)-aminocarbonyl group in acidic- or alkaline aqueous medium, c) reacting a compound of formula (I) wherein X is a lower alkyloxy-carbonyl group with an appropriate amine in a suitable reaction-inert solvent, d) reacting a compound of formula (I) wherein X is an aminocarbonyl-or a lower alkylaminocarbonyl group with an appropriate alkyl-halide, e) reducing a compound of formula (I) wherein X is a carboxyl- or a lower alkyloxycarbonyl group with a suitable metal hydride or diborane, f) stirring a compound of formula (I) wherein X is a hydroxyl group in a suitable oxidizing medium, g) reacting a compound of formula (I) wherein X is a hydroxymethyl group with an appropriate alkyl halide in the presence of a suitable base, h) stirring a compound of formula (I) wherein X is a lower alkyloxy-methyl radical in a medium containing an appropriate Lewis acid, and i) catalytically hydrogenating a compound of formula (I) wherein one of R3 and R4 is a nitro radical in a suitable solvent; and, if desired, converting the compounds of formula (I) into the therapeutically active non-toxic acid-addition salt form by treatment with an appro-priate acid or, conversely, converting the acid-addition salt into the free base form with alkali; and/or preparing stereochemically iso-meric forms thereof.
2. The process according to claim 1 wherein R is a radical of formula (b) wherein Q is diarylmethyl and Alk is a 1,3-propanediyl radical.
3. The process according to claim 1 wherein R is a radical of formula (b) wherein Q is diarylmethyl and Alk is 1,3-propanediyl, X is aminocarbonyl, m is 1 and R1 and R2 are both hydrogen.
4. A process of preparing a chemical compound selected from the group consisting of 3-(aminocarbonyl)-4-[4,4-bis(4-fluorophenyl)-butyl]7-N-2,6-dichlorophenyl)-1-piperazineacetamide, the pharma-ceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, characterized by reacting 1-[4,4-bis(4-fluorophenyl)butyl]-2-piperazinecarboxamide with 2-chloro-N-(2,6-dichlorophenyl)acetamide, and, if desired, preparing a pharmaceutical-ly acceptable acid addition salt thereof.
5. A chemical compound having the formula (I), the stereochemically isomeric forms and the pharmaceutically acceptable acid addition salts thereof, wherein R1 is a member selected from the group consisting of hydro-gen and lower alkyl;

X is a member selected from the group consisting of hydroxy-lower alkyl, lower alkyloxylower alkyl, aminocarbonyl, mono- and di(lower alkyl)aminocarbonyl, carboxyl, lower alkyloxycarbonyl, (aminocarbonyl)lower alkyl, [mono- and di(lower alkyl)aminocarbonyl]-lower alkyl, carboxylower alkyl, (lower alkyloxycarbonyl)lower alkyl and (hydroxylower alkyl)aminocarbonyl;

m is the integer 1 or 2;

R2 is a member selected from the group consisting of hydrogen and lower alkyl;

R3, R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower alkyloxy, halo, trifluoromethyl, lower alkylcarbonyl, aminocarbonyl, lower alkyloxycarbonyl, cyano, amino, mono- and di(lower alkyl)amino, (lower alkylcarbonyl)amino and (aminocarbonyl)amino, while R3 may be nitro or R3 and R4 may both be nitro; and R is a member selected from the group consisting of a radical having the formula (a) wherein Ar1 and Ar2 are each an aryl radical; and a radical having the formula -Alk-Q (b) wherein Alk is an alkanediyl radical or a lower alkenediyl radical, said lower alkanediyl radical being optionally substi-tuted by a hydroxy- or a lower alkyl radical; and Q is a member selected from the group consisting of aryl, aryloxy, diarylmethoxy, 2,2-diarylethenyl, diaryl-methylcarbonyl, arylcarbonyl, mono- and diaryl-aminocarbonyl, diarylmethyl, the methyl moiety in said diarylmethyl group being optionally substituted with a cyano-, an aminocarbonyl-, a mono- or di-lower alkylaminocarbonyl- or a lower alkyloxy-carbonyl radical, arylamino, said amino moiety being optionally substituted with an aryl-, an arylcarbonyl-, a lower alkylcarbonyl-, an arylsulfonyl- or a lower alkyl-sulfonyl radical, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, being optionally substituted in the 5- or 6-position by halo, 10H-phenothiazin-10-ylcarbonyl, being optionally substituted by a halo atom, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl, 1-aryl-1,3-dihydroisobenzofuran-1-yl, and 2,2-diaryl-1,3-dioxolan-4-yl;

wherein aryl is a member selected from the group consisting of phenyl, substituted phenyl, naphthalenyl, thienyl and pyridinyl, said substituted phenyl having from 1 to 2 substituents, each independently selected from the group consisting of halo and (halo-substituted phenyl)carbonyl whenever prepared or produced by the process of claim 1 or by their obvious chemical equivalents thereof.
6. A chemical compound according to claim 5 wherein R
is a radical of formula (b) and Q is diarylmethyl and Alk is a 1,3-propanediyl radical whenever prepared or produced by the process of claim 2 or by their obvious chemical equivalents thereof.
7. A chemical compound according to claim 5 wherein R is a radical of formula (b) wherein Q is diarylmethyl and Alk is 1,3-propanediyl, X is aminocarbonyl, m is 1 and R1 and R2 are both hydrogen whenever prepared or produced by the process of claim 3 or by their obvious chemical equivalents thereof.
8. A chemical compound selected from the group consisting of 3-(aminocarbonyl)-4-[4,4-bis(4-fluorophenyl)butyl]-N-(2,6-dichlorophenyl)-1-piperazineacetamide, the stereochemically isomeric forms and the pharmaceutically acceptable acid addition salts thereof whenever prepared or produced by the process of claim 4 or by their obvious chemical equivalents thereof.
CA000403950A 1981-06-23 1982-05-28 N-aryl-piperazinealkanamides Expired CA1210395A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27662481A 1981-06-23 1981-06-23
US276,624 1981-06-23
US06/362,814 US4766125A (en) 1981-06-23 1982-03-29 N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US362,814 1982-03-29

Publications (1)

Publication Number Publication Date
CA1210395A true CA1210395A (en) 1986-08-26

Family

ID=26958051

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000403950A Expired CA1210395A (en) 1981-06-23 1982-05-28 N-aryl-piperazinealkanamides

Country Status (17)

Country Link
US (1) US4766125A (en)
EP (1) EP0068544B1 (en)
KR (1) KR870001521B1 (en)
AU (1) AU547524B2 (en)
CA (1) CA1210395A (en)
CS (1) CS381991A3 (en)
DE (1) DE3276482D1 (en)
DK (1) DK149949C (en)
ES (1) ES513366A0 (en)
FI (1) FI75810C (en)
GR (1) GR76088B (en)
HU (1) HU189149B (en)
IE (1) IE53465B1 (en)
IL (1) IL66099A0 (en)
NO (1) NO163691C (en)
NZ (1) NZ200935A (en)
PT (1) PT75101B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558129A (en) * 1983-05-18 1985-12-10 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
FR2558162B1 (en) * 1984-01-17 1986-04-25 Adir NOVEL XANTHINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
US4968684A (en) * 1987-04-01 1990-11-06 Janssen Pharmaceutica N.V. Method of improving sleep
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US4880808A (en) * 1987-04-01 1989-11-14 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for improving sleep
DE3715763A1 (en) * 1987-05-12 1988-11-24 Hoechst Ag DIARYLALKYL-SUBSTITUTED ALKYLAMINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THE SAME
US5840896A (en) * 1989-11-22 1998-11-24 Janssen Pharmaceutica, N.V. Method of preventing or limiting reperfusion damage
DK0577171T3 (en) * 1989-11-22 2002-06-03 Janssen Pharmaceutica Nv Use of piperazine acetamide derivatives for reperfusion injury
DK0582164T3 (en) * 1992-07-31 1999-08-23 Bristol Myers Squibb Co Adenosine reuptake inhibitory derivatives of diphenyloxazoles, thiazoles and imidazoles
SE9202266D0 (en) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab NOVEL PIPERAZINE CARBOXAMIDES
DE4404249C2 (en) * 1994-02-10 2001-10-18 Basf Ag Substituted cycloalkyl-piperazinylethanol, their preparation and medicaments containing them
WO1995029169A2 (en) * 1994-04-20 1995-11-02 Lonza Ag Process for preparing 2-piperazine carboxylic acid derivatives
KR100227231B1 (en) * 1994-10-27 1999-11-01 디르크 반테 Apolipoprotein-b synthesis inhibitors
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
EP0870502A3 (en) * 1997-04-10 2001-04-04 Kyowa Hakko Kogyo Co., Ltd. Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
DE69814089T2 (en) * 1997-06-16 2004-02-19 Janssen Pharmaceutica N.V. USE OF A DRAFLAZINE ANALOGUE FOR TREATMENT
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US20040266784A1 (en) * 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
CA2657986A1 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
US6638970B2 (en) 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
JP4370164B2 (en) * 2001-08-14 2009-11-25 富山化学工業株式会社 Novel virus growth inhibition and virucidal methods and novel pyrazine nucleotide pyrazine nucleoside analogues
US7192939B2 (en) * 2002-01-30 2007-03-20 Montana State University Pestalotiopsis microsporia isolates and compounds derived therefrom
EP1567525B1 (en) * 2002-12-05 2007-06-27 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
ATE443058T1 (en) * 2003-01-03 2009-10-15 Cv Therapeutics Inc SUBSTITUTED HETEROCYCLIC COMPOUNDS
AU2004209522A1 (en) * 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
EP1644345A1 (en) * 2003-06-23 2006-04-12 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
KR20060124646A (en) 2003-12-18 2006-12-05 씨브이 쎄러퓨틱스, 인코포레이티드 1-akan-2-ol substituted piperazine and piperidine compounds
US20050227999A1 (en) * 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
WO2007133481A2 (en) * 2006-05-11 2007-11-22 Neuromed Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
JP5523993B2 (en) 2010-08-31 2014-06-18 富士フイルム株式会社 Method for producing acid halide and acid halide
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
CN102285962B (en) * 2011-06-23 2013-04-10 中国药科大学 Phenoxy alkyl piperazine compounds, preparation method thereof and medicinal use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL276807A (en) *
US2997473A (en) * 1958-07-05 1961-08-22 Nederlansche Combinatie Voor C New 2-substituted piperazine derivatives with central stimulating activity
NL137318C (en) * 1964-06-09
DE1670200A1 (en) * 1967-03-22 1972-03-02 Byk Gulden Lomberg Chem Fab New aryl-substituted piperazinylcarboxylic acid anilides and processes for their preparation
GB1196721A (en) * 1968-02-23 1970-07-01 Ici Ltd Piperazine Derivatives
DE1795362A1 (en) * 1968-09-19 1972-01-05 Boehringer Mannheim Gmbh Basic ethers and methods of making them
FR8436M (en) * 1968-11-14 1971-07-15
FR2267104A1 (en) * 1974-04-12 1975-11-07 Ferlux Labo Sa Hypotensive and antiarrhythmic piperazines - 1-(3-phenoxy-2-hydroxy propyl)-4-substd. piperazines
FR2287818A1 (en) * 1974-10-11 1976-05-07 Matsushita Electric Ind Co Ltd VIDEO AMPLIFIER
DE2604845A1 (en) * 1976-02-07 1977-08-18 Knoll Ag NEW PIPERAZINE DERIVATIVES

Also Published As

Publication number Publication date
PT75101B (en) 1985-01-07
NO163691C (en) 1990-07-04
CS381991A3 (en) 1992-05-13
DK280182A (en) 1982-12-24
ES8307763A1 (en) 1983-08-01
FI75810C (en) 1988-08-08
KR840000515A (en) 1984-02-22
AU8508482A (en) 1983-01-06
AU547524B2 (en) 1985-10-24
DK149949B (en) 1986-11-03
HU189149B (en) 1986-06-30
PT75101A (en) 1982-07-01
NO163691B (en) 1990-03-26
NO822087L (en) 1982-12-27
IE53465B1 (en) 1988-11-23
KR870001521B1 (en) 1987-08-22
US4766125A (en) 1988-08-23
FI822243L (en) 1982-12-24
DK149949C (en) 1987-06-15
GR76088B (en) 1984-08-03
FI822243A0 (en) 1982-06-22
IL66099A0 (en) 1982-09-30
DE3276482D1 (en) 1987-07-09
FI75810B (en) 1988-04-29
ES513366A0 (en) 1983-08-01
EP0068544A3 (en) 1983-05-11
NZ200935A (en) 1984-11-09
EP0068544A2 (en) 1983-01-05
IE821476L (en) 1982-12-23
EP0068544B1 (en) 1987-06-03

Similar Documents

Publication Publication Date Title
CA1210395A (en) N-aryl-piperazinealkanamides
US4329353A (en) 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
US4443451A (en) Bicyclic pyrimidin-5-one derivatives
US4925853A (en) Benzimidazoles as 5-lipoxygenase inhibitors
US4711899A (en) 2-(4-benzoyl-1-piperidyl)-1-phenylalkanol derivatives
US5137896A (en) N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1327579C (en) Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
CA1217484A (en) N-aryl-a-amino-carboxamides
JPS62114987A (en) Novel 4-benzyl-1-(2h)-phthaladinone derivative, its production and antiallergic agent containing said derivative
US4066648A (en) Isochroman derivatives
US4369184A (en) 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
JPH0692404B2 (en) 5HT (3) Aryl thiazolyl imidazoles as antagonists
US4548938A (en) 5-H-1,3,4-thiadiazolo[3,2-a]pyrimidin-5-one compounds
US3147270A (en) Substituted 2-imidazolines
DE3101798A1 (en) "NEW DERIVATIVES OF 3,4,5-TRIMETHOXYCINNAMOYL PIPERAZINE, THE SALTS THEREOF, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES"
US4910213A (en) Antimycotic agents
CA1161438A (en) 1-(4-aryl-cyclohexyl)piperidine derivatives
US4197304A (en) N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
US4529727A (en) Pyrimido[2,1-b][1,3]-thiazines
IE61019B1 (en) (Benzofuran-2-yl) imidazoles having pharmaceutical activity, their salts and relevant production processes
US4151286A (en) N-aryl-N-(1-L-4-piperidinyl)-arylacetamides
FI65427C (en) FORM OF FARANK CARBONYLOXIPROPANPIPERAZINE DERIVATIVES
US4810792A (en) Piperidine intermediates
US4197303A (en) N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
CA1205746A (en) Anticonvulsant active substituted n-alkyl imidazoles

Legal Events

Date Code Title Description
MKEX Expiry